Kraig Biocraft Laboratories (KBLB) 10-Q/A 31 Dec 13 2013 Q2 Quarterly report (amended) Financial data

Document_and_Entity_Informatio

Document and Entity Information	6 Months Ended
	Jun. 30, 2013	Aug. 16, 2013
Document And Entity Information	'	'
Entity Registrant Name	'Kraig Biocraft Laboratories, Inc	'
Entity Central Index Key	'0001413119	'
Document Type	'10-Q	'
Document Period End Date	30-Jun-13	'
Amendment Flag	'true	'
Amendment Description	'This amendment is being filed to comply with regulations	'
Current Fiscal Year End Date	'--12-31	'
Is Entity a Well-known Seasoned Issuer?	'No	'
Is Entity a Voluntary Filer?	'No	'
Is Entity's Reporting Status Current?	'Yes	'
Entity Filer Category	'Smaller Reporting Company	'
Entity Common Stock, Shares Outstanding	'	621,107,783
Document Fiscal Period Focus	'Q2	'
Document Fiscal Year Focus	'2013	'

Condensed_Balance_Sheets_Unaud

Condensed Balance Sheets (Unaudited) (USD $)	Jun. 30, 2013	Dec. 31, 2012
ASSETS	'	'
Cash	$123,751	$53,782
Prepaid expenses	1,577	2,270
Loan receivable	'	6,000
Interest receivable	'	192
Total Current Assets	125,328	62,244
Property and Equipment, net	13,739	16,508
Total Assets	139,067	78,752
LIABILITIES AND STOCKHOLDERS DEFICIT	'	'
Accounts payable and accrued expenses	468,195	329,226
Current portion of loan payable	4,102	4,377
Royalty agreement payable - related party	66,000	66,000
Accrued expenses - related party	930,483	804,187
Loan payable - related party	150,000	'
Total Current Liabilities	1,618,780	1,203,790
Long Term Liabilities	'	'
Convertible note payable - net of debt discount	5,000	5,000
Loan payable, net of current portion	2,951	4,378
Total Liabilities	1,626,731	1,213,168
Commitments and Contingencies	'	'
Stockholders Deficit	'	'
Preferred stock, no par value; unlimited shares authorized, none issued and outstanding	'	'
Common stock Class A, no par value; unlimited shares authorized, 607,729,515 and 603,269,838 shares issued and outstanding, respectively	6,585,920	6,360,920
Common stock Class B, no par value; unlimited shares authorized, no shares issued and outstanding	'	'
Common Stock Issuable,1,122,311 and 1,122,311 shares, respectively	22,000	22,000
Additional paid-in capital	1,320,337	1,320,337
Deficit accumulated during the development stage	-9,415,921	-8,837,673
Total Stockholders Deficit	-1,487,664	-1,134,416
Total Liabilities and Stockholders Deficit	$139,067	$78,752

Condensed_Balance_Sheets_Unaud1

Condensed Balance Sheets (Unaudited) (Parenthetical) (USD $)	Jun. 30, 2013	Dec. 31, 2012
Stockholders equity:	'	'
Preferred stock, par value	$0	$0
Preferred stock, issued shares	0	0
Preferred stock, outstanding shares	0	0
Common stock Class A, par value	$0	$0
Common stock Class A, issued shares	607,729,515	603,269,838
Common stock Class A, outstanding shares	607,729,515	603,269,838
Common stock Class B, par value	$0	$0
Common stock Class B, issued shares	0	0
Common stock Class B, outstanding shares	0	0
Common Stock Issuable, Shares	1,122,311	1,122,311

Condensed_Statements_of_Operat

Condensed Statements of Operations (Unaudited) (USD $)	3 Months Ended		6 Months Ended		83 Months Ended
	Jun. 30, 2013	Jun. 30, 2012	Jun. 30, 2013	Jun. 30, 2012	Jun. 30, 2013
Income Statement [Abstract]	'	'	'	'	'
Revenue	'	'	'	'	'
Operating Expenses	'	'	'	'	'
General and Administrative	33,330	230,176	60,827	275,969	2,000,326
Public Relations	'	'	'	'	619,890
Amrotization of Debt Discount	'	'	'	'	120,000
Professional Fees	28,605	11,651	45,472	33,248	380,547
Officer's Salary	58,899	50,000	117,888	105,650	1,721,402
Contract Settlement	'	'	'	'	107,143
Research and Development	164,765	210,000	320,050	210,000	1,622,059
Total Operating Expenses	285,599	501,827	544,237	624,867	6,571,367
Loss from Operations	-285,599	-501,827	-544,237	-624,867	-6,571,367
Other Income/(Expenses)	'	'	'	'	'
Other income	'	3,000	'	3,000	7,881
Interest income	'	55	47	100	239
Change in fair value of embedded derivative liability	'	'	'	'	-2,790,185
Change in fair value of embedded derivative liability- related party	'	'	'	'	119,485
Interest expense	-17,436	-15,036	-34,061	-30,073	-181,974
Total Other Income/(Expenses)	-17,436	-11,981	-34,014	-26,973	-2,844,554
Net (Income) Loss before Provision for Income Taxes	-303,035	-513,808	-578,251	-651,840	-9,415,921
Provision for Income Taxes	'	'	'	'	'
Net Income (Loss)	($303,035)	($513,808)	($578,251)	($651,840)	($9,415,921)
Net Income (Loss) Per Share - Basic and Diluted	$0	$0	$0	$0	'
Weighted average number of shares outstanding during the period - Basic and Diluted	607,591,936	591,010,940	606,208,262	590,839,237	'

Condensed_Statements_of_Cash_F

Condensed Statements of Cash Flows (Unaudited) (USD $)	6 Months Ended		83 Months Ended
	Jun. 30, 2013	Jun. 30, 2012	Jun. 30, 2013
Cash Flows From Operating Activities:	'	'	'
Net Loss	($578,251)	($651,840)	($9,415,921)
Adjustments to reconcile net loss to net cash used in operations	'	'	'
Depreciation expense	2,769	2,776	14,175
Stock issuable for services	'	'	22,000
Change in Fair Value of Derivative Liability	'	'	2,790,703
Stock issued for services	'	510,000	1,458,180
Warrants issued to employees	'	'	126,435
Warrants issued to consultants	'	'	568,000
Deferred compensation realized	'	'	200,000
Changes in operating assets and liabilities:	'	'	'
(Increase) Decrease in prepaid expenses	693	-4,000	-1,577
Increase in accrued expenses and other payables - related party	126,287	70,652	1,495,838
Increase in accounts payable	139,026	-266,828	468,252
Net Cash Used In Operating Activities	-309,476	-339,240	-2,273,915
Cash Flows From Investing Activities:	'	'	'
Loan receivable	'	'	-6,000
Write off of note receivable	6,000	'	6,000
Interest receivable	-46	-100	-238
Write off of interest receivable	192	'	238
Purchase of Fixed Assets and Domain Name	'	'	-27,914
Net Cash Used In Investing Activities	6,146	-100	-27,914
Cash Flows From Financing Activities:	'	'	'
Proceeds from Notes Payable - Stockholder	150,000	'	150,000
Proceeds from issuance of convertible note	'	'	120,000
Loan payable	-1,701	-2,184	7,053
Proceeds from issuance of common stock	225,000	400,000	2,148,527
Net Cash Provided by Financing Activities	373,299	397,816	2,425,580
Net Increase (Decrease) in Cash	69,969	58,476	123,751
Cash at Beginning of Period	53,782	195,409	'
Cash at End of Period	123,751	253,885	123,751
Supplemental disclosure of cash flow information:	'	'	'
Cash paid for interest	'	'	'
Cash paid for taxes	'	'	'
Supplemental disclosure of non-cash investing and financing activities:	'	'	'
Shares issued in connection with cashless warrants exercise	'	'	2,569,838
Shares issued in connection with convertible note payable	'	'	115,000
Beneficial conversion feature on convertible notes and related debt discount	'	'	$120,000

Condensed_Statement_of_Changes

Condensed Statement of Changes in Stockholders Deficit (Unaudited) (USD $)	Preferred Stock	Common Stock - Class A	Common Stock - Class B	Common Stock - Class A Shares to be Issued	Additional Paid-In Capital	Deferred Compensation	Deficit Accumulated during Development Stage	Total
Beginning Balance, Amount at Apr. 24, 2006	'	'	'	'	'	'	'	'
Beginning Balance, Shares at Apr. 24, 2006	'	'	'	'	'	'	'	'
Stock issued to founder, Shares	'	332,292,000	'	'	'	'	'	'
Stock issued to founder, Amount	'	180	'	'	'	'	'	'
Stock issued for services, Shares	'	18,200,000	'	'	'	'	'	'
Stock issued for services, Amount	'	145,600	'	'	'	'	'	140,000
Stock contributed by shareholder	'	-11,666,500	'	'	'	'	'	'
Stock issued for cash, Shares	'	8,000	'	'	'	'	'	'
Stock issued for cash, Amount	'	400	'	'	'	'	'	400
Fair value of warrants issued	'	'	'	'	126,435	'	'	'
Net Loss	'	'	'	'	'	'	-530,321	-530,321
Ending Balance, Amount at Dec. 31, 2006	'	146,180	'	'	126,435	'	-530,321	-257,706
Ending Balance, Shares at Dec. 31, 2006	'	338,833,500	'	'	'	'	'	'
Stock issued for services, Shares	600,000	'	'	'	'	'	'	'
Stock issued for services, Amount	6,000	'	'	'	'	'	'	6,000
Stock issued for cash, Shares	129,790,000	'	'	'	'	'	'	'
Stock issued for cash, Amount	526,495	'	'	'	'	'	'	526,495
Stock issued in connection to cash offering, Shares	28,125,000	'	'	'	'	'	'	'
Stock issued in connection to cash offering, Amount	84,375	'	'	'	-84,375	'	'	'
Net Loss	'	'	'	'	'	'	-472,986	-472,986
Ending Balance, Amount at Dec. 31, 2007	'	779,050	'	'	42,060	'	-1,003,307	-182,197
Ending Balance, Shares at Dec. 31, 2007	'	499,348,500	'	'	'	'	'	'
Shares issuable for services ($0.01/Share), Shares	'	'	'	400,000	'	'	'	'
Shares issuable for services ($0.01/Share), Amount	'	'	'	4,000	'	'	'	4,000
Net Loss	'	'	'	'	'	'	-1,721,156	-1,721,156
Ending Balance, Amount at Dec. 31, 2008	'	779,050	'	4,000	42,060	'	-2,724,463	-1,899,353
Ending Balance, Shares at Dec. 31, 2008	'	499,348,500	'	400,000	'	'	'	'
Stock issued for services, Shares	'	280,000	'	10,722,311	'	'	'	'
Stock issued for services, Amount	'	14,000	'	218,000	'	-103,333	'	128,000
Stock issued for cash, Shares	'	2,866,599	'	'	'	'	'	'
Stock issued for cash, Amount	'	28,000	'	'	'	'	'	28,000
Net Loss	'	'	'	'	'	'	-1,432,091	-1,432,091
Ending Balance, Amount at Dec. 31, 2009	'	821,050	'	222,000	42,060	-103,333	-4,156,554	-3,174,777
Ending Balance, Shares at Dec. 31, 2009	'	502,495,099	'	11,122,311	'	'	'	'
Stock issued for services, Shares	'	19,293,415	'	'	'	'	'	'
Stock issued for services, Amount	'	414,400	'	'	'	'	'	75,400
Warrants issued for services	'	'	'	'	168,000	-168,000	'	'
Stock issued in connection with convertible note conversion, Shares	'	6,548,620	'	'	'	'	'	'
Stock issued in connection with convertible note conversion, Amount	'	115,000	'	'	'	'	'	115,000
Stock issued for cash, Shares	'	20,003,968	'	'	'	'	'	'
Stock issued for cash, Amount	'	473,632	'	'	'	'	'	273,632
Exercise of warrants in exchange for stock	'	5,177,801	'	'	'	'	'	'
Exercise of warrants in exchange for stock	'	10,000	'	'	677,908	'	'	687,908
Deferred compensation realized	'	'	'	'	'	250,333	'	250,333
Forgiveness of accrued payable to related party	'	'	'	'	499,412	'	'	499,412
Forgiveness of derivative liability to related party	'	'	'	'	2,102,795	'	'	2,102,795
Net Loss	'	'	'	'	'	'	-1,782,888	-1,782,888
Ending Balance, Amount at Dec. 31, 2010	'	1,834,082	'	22,000	3,490,175	-26,000	-5,939,442	-619,185
Ending Balance, Shares at Dec. 31, 2010	'	553,518,903	'	1,122,311	'	'	'	'
Stock issued for services, Shares	'	2,029,412	'	'	'	'	'	'
Stock issued for services, Amount	'	140,000	'	'	'	'	'	140,000
Stock issued for cash, Shares	'	9,204,111	'	'	'	'	'	'
Stock issued for cash, Amount	'	600,000	'	'	'	'	'	600,000
Exercise of warrants in exchange for stock	'	19,767,985	'	'	'	'	'	'
Exercise of warrants in exchange for stock	'	2,569,838	'	'	-2,569,838	'	'	'
Deferred compensation realized	'	'	'	'	'	26,000	'	26,000
Net Loss	'	'	'	'	'	'	-1,295,310	-1,295,310
Ending Balance, Amount at Dec. 31, 2011	'	5,385,920	'	22,000	920,337	'	-7,234,752	-906,495
Ending Balance, Shares at Dec. 31, 2011	'	586,720,411	'	1,122,311	'	'	'	'
Stock issued for services, Shares	'	7,500,000	'	'	'	'	'	'
Stock issued for services, Amount	'	550,000	'	'	'	'	'	550,000
Stock issued for cash, Shares	'	9,049,427	'	'	'	'	'	'
Stock issued for cash, Amount	'	425,000	'	'	'	'	'	425,000
Net Loss	'	'	'	'	'	'	-1,602,921	-1,602,921
Ending Balance, Amount at Dec. 31, 2012	'	6,360,920	'	22,000	1,320,337	'	-8,837,673	-1,134,416
Ending Balance, Shares at Dec. 31, 2012	'	603,269,838	'	1,122,311	'	'	'	'
Stock issued in connection with convertible note conversion, Amount	'	'	'	'	'	'	'	'
Stock issued for cash, Shares	'	3,613,877	'	'	'	'	'	'
Stock issued for cash, Amount	'	225,000	'	'	'	'	'	225,000
Make up shares issued for the transaction entred during the December 31, 2012 year end	'	845,800	'	'	'	'	'	'
Net Loss	'	'	'	'	'	'	-578,251	-578,251
Ending Balance, Amount at Jun. 30, 2013	'	$6,585,920	'	$22,000	$1,320,337	'	($9,415,924)	($1,487,664)
Ending Balance, Shares at Jun. 30, 2013	'	607,729,515	'	1,122,311	'	'	'	'

1_SUMMARY_OF_SIGNIFICANT_ACCOU

1. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND ORGANIZATION	6 Months Ended
	Jun. 30, 2013
Notes to Financial Statements	'
1. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND ORGANIZATION	'
	(A)  Basis of Presentation
	The accompanying unaudited condensed financial statements have been prepared in accordance with accounting principles generally accepted in The United States of America and the rules and regulations of the Securities and Exchange Commission for interim financial information.  Accordingly, they do not include all the information necessary for a comprehensive presentation of financial position and results of operations.
	It is management's opinion, however that all material adjustments (consisting of normal recurring adjustments) have been made which are necessary for a fair financial statements presentation.  The results for the interim period are not necessarily indicative of the results to be expected for the year.
	Activities during the development stage include developing the business plan and raising capital.
	(B) Use of Estimates
	In preparing financial statements in conformity with generally accepted accounting principles, management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and revenues and expenses during the reported period.  Actual results could differ from those estimates.
	(C) Cash
	For purposes of the cash flow statements, the Company considers all highly liquid investments with original maturities of three months or less at the time of purchase to be cash equivalents.
	(D) Loss Per Share
	Basic and diluted net loss per common share is computed based upon the weighted average common shares outstanding as defined by FASB Accounting Standards Codification No. 260, “Earnings per Share.”  As of June 30, 2013 and 2012, warrants were not included in the computation of income/ (loss) per share because their inclusion is anti-dilutive.
	The computation of basic and diluted loss per share at June 30, 2013 and December 31, 2012 excludes the common stock equivalents of the following potentially dilutive securities because their inclusion would be anti-dilutive:
		June 30,		December 31,
		2013		2012
	Stock Warrants (Exercise price - $0.001/share)		10,000,000		10,000,000
	(E) Research and Development Costs
	The Company expenses all research and development costs as incurred for which there is no alternative future use. These costs also include the expensing of employee compensation and employee stock based compensation.
	(F) Income Taxes
	The Company accounts for income taxes under FASB Codification Topic 740-10-25 (“ASC 740-10-25”).  Under ASC 740-10-25, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases.  Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled.  Under ASC 740-10-25, the effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date.
	Effective January 1, 2009, the Company adopted guidance regarding accounting for uncertainty in income taxes. This guidance clarifies the accounting for income taxes by prescribing the minimum recognition threshold an income tax position is required to meet before being recognized in the financial statements and applies to all federal or state income tax positions. Each income tax position is assessed using a two step process. A determination is first made as to whether it is more likely than not that the income tax position will be sustained, based upon technical merits, upon examination by the taxing authorities. If the income tax position is expected to meet the more likely than not criteria, the benefit recorded in the financial statements equals the largest amount that is greater than 50% likely to be realized upon its ultimate settlement. As of December 31, 2012 and 2011 there were no amounts that had been accrued in respect to uncertain tax positions.
	None of the Company’s federal or state income tax returns is currently under examination by the Internal Revenue Service (“IRS”) or state authorities.  However, fiscal years 2009 and later remain subject to examination by the IRS and respective states.
	(G) Derivative Financial Instruments
	Fair value accounting requires bifurcation of embedded derivative instruments such as conversion features in convertible debt or equity instruments, and measurement of their fair value for accounting purposes. In determining the appropriate fair value, the Company uses the Black-Scholes option-pricing model. In assessing the convertible debt instruments, management determines if the convertible debt host instrument is conventional convertible debt and further if there is a beneficial conversion feature requiring measurement. If the instrument is not considered conventional convertible debt, the Company will continue its evaluation process of these instruments as derivative financial instruments.
	Once determined, derivative liabilities are adjusted to reflect fair value at each reporting period end, with any increase or decrease in the fair value being recorded in results of operations as an adjustment to fair value of derivatives. In addition, the fair value of freestanding derivative instruments such as warrants, are also valued using the Black-Scholes option-pricing model.
	(H) Stock-Based Compensation
	In December 2004, the FASB issued FASB Accounting Standards Codification No. 718, Compensation – Stock Compensation.  Under FASB Accounting Standards Codification No. 718, companies are required to measure the compensation costs of share-based compensation arrangements based on the grant-date fair value and recognize the costs in the financial statements over the period during which employees are required to provide services. Share-based compensation arrangements include stock options, restricted share plans, performance-based awards, share appreciation rights and employee share purchase plans.  As such, compensation cost is measured on the date of grant at their fair value.  Such compensation amounts, if any, are amortized over the respective vesting periods of the option grant.  The Company applies this statement prospectively.
	Equity instruments (“instruments”) issued to other than employees are recorded on the basis of the fair value of the instruments, as required by FASB Accounting Standards Codification No. 718.  FASB Accounting Standards Codification No. 505, Equity Based Payments to Non-Employees defines the measurement date and recognition period for such instruments.  In general, the measurement date is when either a (a) performance commitment, as defined, is reached or (b) the earlier of (i) the non-employee performance is complete or (ii) the instruments are vested. The measured value related to the instruments is recognized over a period based on the facts and circumstances of each particular grant as defined in the FASB Accounting Standards Codification.
	(I) Business Segments
	The Company operates in one segment and therefore segment information is not presented.
	(J) Recent Accounting Pronouncements
	In February 2013, FASB issued Accounting Standards Update 2013-04, Liabilities (Topic 405): Obligations Resulting from Joint and Several Liability Arrangements for Which the Total Amount of the Obligation Is Fixed at the Reporting Date (a consensus of the FASB Emerging Issues Task Force). This guidance requires an entity to measure obligations resulting from joint and several liability arrangements for which the total amount of the obligation within the scope of this guidance is fixed at the reporting date. This stipulates that (1) it will include the amount the entity agreed to pay for the arrangement between them and the other entities that are also obligated to the liability and (2) any additional amount the entity expects to pay on behalf of the other entities. The objective of this update is to provide guidance for the recognition, measurement, and disclosure of obligations resulting from joint and several liability arrangements. The amendments in this update are effective for fiscal periods (and interim reporting periods within those years) beginning after December 15, 2013. This standard is not expected to have a material impact on the Company’s reported results of operations or financial position.
	In February 2013, FASB issued Accounting Standards Update 2013-02, Comprehensive Income (Topic 220): Reporting of Amounts Reclassified out of Accumulated Other Comprehensive Income. This update requires an entity to provide information about the amount reclassified out of accumulated other comprehensive income by component. The entity is also required to disclose significant amounts reclassified out of accumulated other comprehensive income by the respective line items of net income but only if the amount reclassified is required under U.S. GAAP to be reclassified to net income in its entirety in the same reporting periods. For other amounts that are not required under U.S. GAAP to be reclassified in their entirety to net income, an entity is required to cross-reference to other discourses required under U.S. GAAP that provide additional detail about those amounts. The objective in this Update is to improve the reporting of reclassifications out of accumulated other comprehensive income. The amendments in this update should be applied prospectively for reporting periods beginning after December 15, 2013. This standard is not expected to have a material impact on the Company’s reported results of operations or financial position.
	(K) Reclassification
	The 2013 financial statements have been reclassified to conform to the 2012 presentation.
	(L) Equipment
	The Company values property and equipment at cost and depreciates these assets using the straight-line method over their expected useful life. The Company uses a five year life for automobiles.
	In accordance with FASB Accounting Standards Codification No. 360, Property, Plant and Equipment, the Company carries long-lived assets at the lower of the carrying amount or fair value. Impairment is evaluated by estimating future undiscounted cash flows expected to result from the use of the asset and its eventual disposition. If the sum of the expected undiscounted future cash flow is less than the carrying amount of the assets, an impairment loss is recognized. Fair value, for purposes of calculating impairment, is measured based on estimated future cash flows, discounted at a market rate of interest.
	There were no impairment losses recorded during the three and six months ended June 30, 2013 and 2012.

2_RESTATEMENT_OF_FINANCIAL_STA

2. RESTATEMENT OF FINANCIAL STATEMENTS	6 Months Ended
	Jun. 30, 2013
Accounting Changes and Error Corrections [Abstract]	'
2. RESTATEMENT OF FINANCIAL STATEMENTS	'
	The audited financial statements  for the year ended December 31, 2012, filed with the SEC on  April 15, 2013, have been restated as a result of management’s determination that the Company’s accounting treatment pertaining to the issuance of 10,000,000 warrants to consultant with a fair value of $400,000 should be recorded as a public relations expense (See Note 8(E)).
	The effect of the restatement on our previously issued audited financial statements as of December 31, 2012 is as follows:
		RESTATED BALANCE SHEET									Note
		As Reported			Adjustments			Restated
	Total Assets	$	78,752		$	-		$	78,752
	Total Liabilities	$	1,213,168		$	-		$	1,213,168
	Commitments and Contingencies
	Stockholders' Deficit
	Preferred stock, no par value; unlimited shares authorized,
	none issued  and outstanding		-			-			-
	Common stock Class A,  no par value; unlimited shares authorized,
	603,269,838 and 586,720,411 shares issued and outstanding, respectively		6,360,920			-			6,360,920
	Common stock Class B,  no par value; unlimited shares authorized,
	no shares issued and outstanding		-			-			-
	Common Stock Issuable, 1,122,311 and 1,122,311 shares, respectively		22,000			-			22,000			1
	Additional paid-in capital		920,337			400,000			1,320,337
	Deferred Compensation		-			-			-
	Deficit accumulated during the development stage		(8,437,673	)		(400,000	)		(8,837,673	)		1
			.
	Total Stockholders' Deficit		(1,134,416	)		-			(1,134,416	)
	Total Liabilities and Stockholders' Deficit	$	78,752		$	-		$	78,752
		RESTATED STATEMENT OF OPERATIONS									Note
		For the Year Ended						For the Year Ended
		31-Dec-12						31-Dec-12
		As Reported			Adjustments			Restated
	Revenue	$	-					$	-
									-
	Operating Expenses								-
	General and Administrative		379,326						379,326
	Public Relations		-			400,000			400,000			1
	Amortization of Debt Discount		-						-
	Professional Fees		48,667						48,667
	Officer's Salary		267,120						267,120
	Contract Settlement		-						-
	Research and Development		465,293						465,293
	Total Operating Expenses		1,160,406			400,000			1,560,406
									-
	Loss from Operations		(1,160,406	)		(400,000	)		(1,560,406	)
									-
	Other Income/(Expenses)								-
	Other income		3,000						3,000
	Interest income		192						192
	Change in fair value of embedded derivative liability		-						-
	Change in fair value of embedded derivative liability-related party		-						-
	Interest expense		(45,707	)					(45,707	)
	Other expense		-						-
	Total Other Income/(Expenses)		(42,515	)		-			(42,515	)
									-
	Net (Income) Loss before Provision for Income Taxes		(1,202,921	)		(400,000	)		(1,602,921	)
									-
	Provision for Income  Taxes		-			-			-
									-
	Net Income (Loss)	$	(1,202,921	)	$	(400,000	)	$	(1,602,921	)
									-
	Net Income (Loss) Per Share  - Basic and Diluted	$	(0.00	)				$	(0.00	)
	Weighted average number of shares outstanding
	during the period - Basic and Diluted		596,143,581						596,143,581
		RESTATED STATEMENT OF OPERATIONS									Note
		For the Period from April 25, 2006 (Inception) to December 31, 2012						For the Period from April 25, 2006 (Inception) to December 31, 2012
		As Reported			Adjustments			Restated
	Revenue	$	-					$	-
									-
	Operating Expenses								-
General and Administrative		1,939,502						1,939,502
Public Relations		219,890			400,000			619,890			1
Amortization of Debt Discount		120,000						120,000
Professional Fees		335,075						335,075
Officer's Salary		1,603,514						1,603,514
Contract Settlement		107,143						107,143
Research and Development		1,302,009						1,302,009
Total Operating Expenses		5,627,133			400,000			6,027,133
								-
Loss from Operations		(5,627,133	)		(400,000	)		(6,027,133	)
								-
Other Income/(Expenses)								-
Other income		7,881						7,881
Interest income		192						192
Change in fair value of embedded derivative liability		(2,790,185	)					(2,790,185	)
Change in fair value of embedded derivative liability-related party		119,485						119,485
Interest expense		(147,913	)					(147,913	)
Total Other Income/(Expenses)		(2,810,540	)		-			(2,810,540	)
								-
Net (Income) Loss before Provision for Income Taxes		(8,437,673	)		(400,000	)		(8,837,673	)
								-
Provision for Income  Taxes		-			-			-
								-
Net Income (Loss)	$	(8,437,673	)	$	(400,000	)	$	(8,837,673	)
								-
	RESTATED STATEMENTS OF CASH FLOWS									Note
	For the Year Ended						For the Year Ended
	31-Dec-12						31-Dec-12
	As Reported			Adjustments			Restated
Cash Flows From Operating Activities:
Net Loss	$	(1,202,921	)	$	(400,000	)	$	(1,602,921	)		1
Adjustments to reconcile net loss to net cash used in operations
Depreciation expense		5,583						5,583
Stock issuable for services		-						-
Change in Fair Value of Derivative Liability		-						-
Stock issued for services		550,000						550,000
Warrants issued to employees		-						-
Warrants issued to consultants		-			400,000			400,000
Deferred compensation realized		-						-
Changes in operating assets and liabilities:								-
(Increase)Decrease in prepaid expenses		(2,270	)					(2,270	)
(Increase)Decrease in other receivables								-
Increase in accrued expenses and other payables - related party		238,977						238,977
Increase in accounts payable		(152,291	)					(152,291	)
Net Cash Used In Operating Activities		(562,922	)		-			(562,922	)
	RESTATED STATEMENTS OF CASH FLOWS									Note
	For the Period from April 25, 2006 (Inception) to December 31,
	2012						For the Period from April 25, 2006 (Inception) to
							December 31,
							2012
	As Reported			Adjustments			Restated
Cash Flows From Operating Activities:
Net Loss	$	(8,437,673	)	$	(400,000	)	$	(8,837,673	)		1
Adjustments to reconcile net loss to net cash used in operations
Depreciation expense		11,406						11,406
Stock issuable for services		22,000						22,000
Change in Fair Value of Derivative Liability		2,790,703						2,790,703
Stock issued for services		1,458,180						1,458,180
Warrants issued to employees		126,435						126,435
Warrants issued to consultants		168,000			400,000			568,000			1
Deferred compensation realized		200,000						200,000
Changes in operating assets and liabilities:								-
(Increase)Decrease in prepaid expenses		(2,270	)					(2,270	)
Increase in accrued expenses and other payables - related party		1,369,600						1,369,600
Increase in accounts payable		329,226						329,226
Net Cash Used In Operating Activities		(1,964,393	)		-			(1,964,393	)
Note:
1.  Adjustment to recongnize 10,000,000 warrants issued to consultant on November 21, 2012, with fair value of $400,000 (See Note 7(E)).
The effect of the restatement on our previously issued unaudited financial statements as of March 31, 2013 and June 30, 2013 is as follows:
	RESTATED STATEMENT OF OPERATIONS									Note
	For the Period from April 25, 2006 (Inception) to						For the Period from April 25, 2006 (Inception) to
	March 31,						March 31,
	2013						2013
	As Reported			Adjustments			Restated
Revenue	$	-					$	-
								-
Operating Expenses								-
General and Administrative		1,967,043						1,967,043
Public Relations		219,890			400,000			619,890			1
Amortization of Debt Discount		120,000						120,000
Professional Fees		351,942						351,942
Officer's Salary		1,662,503						1,662,503
Contract Settlement		107,143						107,143
Research and Development		1,457,292						1,457,292
Total Operating Expenses		5,885,813			400,000			6,285,813
								-
Loss from Operations		(5,885,813	)		(400,000	)		(6,285,813	)
								-
Other Income/(Expenses)								-
Other income		7,881						7,881
Interest income		192						192
Change in fair value of embedded derivative liability		(2,790,185	)					(2,790,185	)
Change in fair value of embedded derivative liability-related party		119,485						119,485
Interest expense		(164,538	)					(164,538	)
Total Other Income/(Expenses)		(2,827,165	)		-			(2,827,165	)
								-
Net (Income) Loss before Provision for Income Taxes		(8,712,978	)		(400,000	)		(9,112,978	)
								-
Provision for Income  Taxes		-			-			-
								-
Net Income (Loss)	$	(8,712,978	)	$	(400,000	)	$	(9,112,978	)
								-
	RESTATED STATEMENT OF OPERATIONS									Note
	For the Period from April 25, 2006 (Inception) to						For the Period from April 25, 2006 (Inception) to
	30-Jun-13						30-Jun-13
	As Reported			Adjustments			Restated
Revenue	$	-					$	-
								-
Operating Expenses								-
General and Administrative		2,000,326						2,000,326
Public Relations		219,890			400,000			619,890			1
Amortization of Debt Discount		120,000						120,000
Professional Fees		380,547						380,547
Officer's Salary		1,721,402						1,721,402
Contract Settlement		107,143						107,143
Research and Development		1,622,059						1,622,059
Total Operating Expenses		6,171,367			400,000			6,571,367
								-
Loss from Operations		(6,171,367	)		(400,000	)		(6,571,367	)
								-
Other Income/(Expenses)								-
Other income		7,881						7,881
Interest income		239						239
Change in fair value of embedded derivative liability		(2,790,185	)					(2,790,185	)
Change in fair value of embedded derivative liability-related party		119,485						119,485
Interest expense		(181,974	)					(181,974	)
Total Other Income/(Expenses)		(2,844,554	)		-			(2,844,554	)
								-
Net (Income) Loss before Provision for Income Taxes		(9,015,921	)		(400,000	)		(9,415,921	)
								-
Provision for Income  Taxes		-			-			-
								-
Net Income (Loss)	$	(9,015,921	)	$	(400,000	)	$	(9,415,921	)

3_GOING_CONCERN

3. GOING CONCERN	6 Months Ended
	Jun. 30, 2013
Organization, Consolidation and Presentation of Financial Statements [Abstract]	'
GOING CONCERN	'
	As reflected in the accompanying financial statements, the Company is in the development stage, has a working capital deficiency of $1,493,455 and stockholders’ deficiency of $1,487,664 and used $2,273,915 of cash in operations from inception.  This raises substantial doubt about its ability to continue as a going concern.  The ability of the Company to continue as a going concern is dependent on the Company’s ability to raise additional capital and implement its business plan.  The financial statements do not include any adjustments that might be necessary if the Company is unable to continue as a going concern.
	Management believes that actions presently being taken to obtain additional funding and implement its strategic plans provide the opportunity for the Company to continue as a going concern.

4_EQUIPMENT

4. EQUIPMENT	6 Months Ended
	Jun. 30, 2013
Property, Plant and Equipment [Abstract]	'
EQUIPMENT	'
	At June 30, 2013 and December 31, 2012 equipment is as follows:
		As of			As of
		June 30,			December 31,
		2013			2012
	Automobile	$	25,828		$	25,828
	Office Equipment		2,086			2,086
	Less Accumulated Depreciation		(14,175	)		(11,406	)
	Total Property and Equipment	$	13,739		$	16,508
	Depreciation and amortization expense for the three months ended June 30, 2013 and 2012 was $1,392 and $1,378 respectively.
	Depreciation and amortization expense for the six months ended June 30, 2013 and 2012 was $2,768 and $2,766 respectively.

5_CONVERTIBLE_DEBT_DEBT_DISCOU

5. CONVERTIBLE DEBT, DEBT DISCOUNT AND FAIR VALUE MEASUREMENT OF DERIVATIVE FINANCIAL INSTRUMENTS	6 Months Ended
	Jun. 30, 2013
Notes to Financial Statements	'
CONVERTIBLE DEBT, DEBT DISCOUNT AND FAIR VALUE MEASUREMENT OF DERIVATIVE FINANCIAL INSTRUMENTS	'
	On July 17, 2009, the Company entered into an agreement with an investor group where the Company will issue up to $120,000 in convertible units.  The debentures will be in the face amount of $10,000 each, mature on December 31, 2010, bear interest at the rate of 5% simple interest per annum, payable at maturity or convertible with the principal, and the principal and interest shall be convertible at the option of the holder at a fixed price of $0.018 per share.  Each debenture shall have a warrant attached exercisable for the purchase of 500,000 shares of common stock.  The warrants shall expired on December 31, 2011, have a cashless exercise provision, and be exercisable at a fixed price of $0.02.  The agreement also requires the investment group to purchase up to $1,000,000 of common stock monthly at the lesser of $75,000 or 200% of the average daily volume multiplied by the average of the daily closing prices for the ten days immediately preceding the exercise date.  Each investment by the investment group is priced at the lowest closing “bid” price of the common stock during the five days immediately before the investment.  The term of the funding shall be the earlier of (a) the drawing down of the entire $1,000,000 or (b) 24 months after the Effective Date, July 17, 2011.  In addition, the Company is required to file and maintain an effective registration statement covering the convertible units, cannot issue more than 5% of its common stock outstanding without the investor group’s consent and must maintain a contractual relationship with a public relations firm, which is related to the investor group (see Note 6(D)). The Company has issued $120,000 of convertible debt to date.   On July 21, 2010, the issuance of 1,799,434 shares was approved by the board of directors in exchange for the $15,000 specified in the put notice (See Note 9).
	The $120,000 convertible debt instrument was determined to have a separate derivative liability instrument requiring bifurcation and the computation of fair value. The conversion price per share equals to the lower of the conversion price and the average closing bid price of the common stock during the 20 trading days prior to and including the date on which the conversion notice is delivered to the holder, however, the mandatory Conversion price shall not be less than $0.005. The Company calculated the estimated fair values of the liabilities for warrant derivative instruments and embedded conversion option derivative instruments with the Black-Scholes option pricing model.
	The fair value of the embedded conversion options at the commitment date was $251,919.  Of the total, $120,000 was assigned to debt discount and $131,919 was recorded as a derivative expense.
	On February 11, 2010 the Company authorized the issuance of 5,694,451 shares of Common Stock for the exercise price of $0.02/share in exchange for $100,000 in convertible note payable and on April 6, 2010 the Company authorized the issuance of 854,169 shares of Common Stock for the exercise price of $0.02/share in exchange for $15,000 in convertible note payable.
	At December 31, 2010, pursuant to the agreement, all outstanding principal and accrued interest on the convertible debt was due, and the conversion rights of the holder terminated.  Accordingly, at December 31, 2010, the Company determined that no derivative liability existed in connection to the outstanding remaining debt of $5,000.
	In addition, on October 4, 2010, the Company issued 5,177,801 shares in connection with the cashless exercise of the 6,000,000 warrants.
	At June 30, 2011 the Company recorded interest expense and related accrued interest payable of $2,466.  The Company also recorded $92,600 for the amortization of debt discount in interest expense on the statement of operations.  The debt discount is being amortized over the life of the convertible debt.

6_LOAN_PAYABLE

6. LOAN PAYABLE	6 Months Ended
	Jun. 30, 2013
Debt Disclosure [Abstract]	'
LOAN PAYABLE	'
	On December 8, 2010 the Company entered into a five year loan agreement with the principal loan amount of $15,828.24. The loan carries an interest rate of 6.94%, and is secured by an automobile.

7_LOAN_PAYABLERELATED_PARTY

7. LOAN PAYABLE-RELATED PARTY	6 Months Ended
	Jun. 30, 2013
Related Party Transactions [Abstract]	'
7. LOAN PAYABLE-RELATED PARTY	'
	On October 6, 2006 the Company received $10,000 from a principal stockholder.    Pursuant to the terms of the loan, the advance bears interest at 12%, is unsecured and matured on May 1, 2007. At June 30, 2011 the Company recorded interest expense and related accrued interest payable of $776.   As of June 30, 2011, the loan principal was repaid in full.
	On December 26, 2006, the Company entered into an addendum to the intellectual property transfer agreement with an officer.  In consideration of the Company issuing either 200,000 preferred shares with the following preferences; no dividends and voting rights equal to 100 common shares per share of preferred stock or the payment of $120,000, the officer agreed to terminate the royalty payments due under the agreement and give title to the exclusive license for the non protective apparel use of the intellectual property to the Company.  On the date of the agreement, the Company did not have any preferred stock authorized with the required preferences.  In accordance with In accordance with FASB Accounting Standards Codification No. 480, Distinguishing Liabilities from Equity, the Company determined that the present value of the payment of $120,000 that was due on December 26, 2007, the one year anniversary of the addendum, should be recorded as an accrued expense until such time as the Company has the ability to assert that it has preferred shares authorized.  As of March 31, 2010, the Company has recorded $120,000 in royalty agreement payable- related party.  On December 21, 2007 the officer extended the due date to July 30, 2008.  On May 30, 2008 the officer extended the due date to March 31, 2009.  On October 10, 2008, the officer extended the due date to the earlier of (a) March 30, 2010 or (b) upon demand by the officer. On March 30, 2010, the officer extended the due date to the earlier of (a) March 30, 2010 or (b) upon demand by the officer.  On September 8, 2009, a payment of $15,000 was paid to the officer. On October 19, 2009 and December 1, 2009, $10,000 was paid to the officer respectfully.  An additional payment of $10,000 was made on January 15, 2010.  During the quarter ending September 30, 2010 an additional payment of $8,000 was made. During the year ended December 31, 2012 an additional payment of $1,000 was made. As of June 30, 2013, the outstanding balance is $66,000.  Additionally, the accrued expenses are accruing 7% interest per year.  As of June 30, 2013 the Company recorded interest expense and related accrued interest payable of $1,005(See Note 9(C)).
	As of June 30, 2013, the Company owes $634,732 in accrued salary to principal stockholder.    On September, 2010, the Company entered into an addendum to the employment agreement whereby all but $250,000 of unpaid back salary will be forgiven by the principal stockholder.  Also, the interest rate was reduced to 3% per year.  In exchange the Company will issue 10,000,000 preferred shares to the principal stockholder no later than September 30, 2011, that date was extended by mutual agreement to December 31, 2012.  The agreement was subsequently extended to October 31, 2013.  As of June 30, 2011, no accrued salary has been converted to Class “A” Common Stock.  On November 10, 2010, the Company entered into an addendum to the employment agreement, effective January 1, 2011 through the December 31, 2015.    The term of the agreement is a five year period at an annual salary of $210,000.  There is a 6% annual increase.  The employee is also to receive a 20% bonsus based on the annual based salary.  Any stock, stock options bonuses have to be approved by the board of directors (See Note 8(A)).
	On February 25, 2013 the Company received $150,000 from a principal stockholder.    Pursuant to the terms of the loan, the advance bears interest at 3%, is unsecured and due on demand. At June 30, 2013 the Company recorded interest expense and related accrued interest payable of $1,543.

8_STOCKHOLDERS_DEFICIT

8. STOCKHOLDERS DEFICIT

6 Months Ended

Jun. 30, 2013

Equity [Abstract]

'

STOCKHOLDERSb DEFICIT

'

(A)        Common Stock Issued for Cash

On April 28, 2006, the Company issued 8,000 shares of common stock for cash of $400 ($0.05 per share).

On January 8, 2007 the Company issued 1,750,000 shares of common stock for $15,000 ($0.01/share).  This agreement was subsequently terminated effective May 23, 2007.

On January 22, 2007 the Company issued 12,000,000 shares of common stock for $103,000 ($0.01/share).   In addition, 9,000,000 shares were issued for $3,000 ($0.0003/share).

On April 4, 2007, the Company issued 1,875,000 shares of common stock for cash of $15,000 ($0.01 per share).

On April 20, 2007, the Company issued 1,875,000 shares of common stock for cash of $15,000 ($0.01 per share).

On May 18, 2007, the Company issued 13,125,000 shares of common stock for cash of $105,000 ($0.01 per share).

On August 28, 2007 the Company entered into a stock purchase agreement to issue 80,495,000 shares common stock in the amount of $241,485 ($0.003/share).

On August 29, 2007 the Company entered into a stock purchase agreement to issue 200,000 shares common stock in the amount of $600 ($0.003/share).

On August 29, 2007 the Company entered into a stock purchase agreement to issue 8,300,000 shares common stock in the amount of $24,900 ($0.003/share).

On September 1, 2007 the Company entered into a stock purchase agreement to issue 25,000 shares common stock in the amount of $75 ($0.003/share).

On September 5, 2007 the Company entered into a stock purchase agreement to issue 120,000 shares common stock in the amount of $360 ($0.003/share).

On September 12, 2007 the Company entered into a stock purchase agreement to issue 1,025,000 shares common stock in the amount of $3,075 ($0.003/share).

In accordance with the May 2007 stock purchase agreement which contains an anti-dilution clause which requires the Company to issue additional common shares under the stock purchase agreement for any subsequent issuance at a price below $.08 per share for a period of 12 months, the Company has issued 28,125,000 additional shares through May 2008 as a result of the subsequent stock issuances at $0.003/share.

On April 24, 2009 the Company issued 2,000,000 shares of common stock for $20,000 ($0.01/share).

On May 22, 2009, the Company issued 500,000 shares of common stock for $5,000 ($0.01/share).

On September 30, 2009, the Company issued 366,599 shares of common stock for $3,000 ($0.01/share).

On May 18, 2010, the Company issued 4,000,000 shares of common stock for cash of $21,642 and in exchange of $6,990 in note payables ($0.007158 per share).

On July 21, 2010, the Company issued 1,875,000 shares of common stock for $15,000 ($0.008/share).

On September 10, 2010, the Company issued 1,351,351 shares of common stock for $20,000 ($0.0148/share).

On September 22, 2010, the Company issued 1,286,765 shares of common stock for $35,000 ($0.0272/share).

On October 15, 2010, the Company issued 1,179,245 shares of common stock for $100,000 ($0.084/share).

On December 7, 2010, the Company issued 1,157,407 shares of common stock for $75,000 ($0.065/share).

On January 25, 2011 the Company issued 1,470,588 shares of common stock for $100,000 ($0.068/share).

On March 22, 2011 the Company issued 2,083,333 shares of common stock for $100,000 ($0.048/share).

On April 18, 2011 the Company issued 1,029,412 shares of common stock for $70,000 ($0.07/share).

On April 22, 2011 the Company issued 1,420,455 shares of common stock for $100,000 ($0.07/share).

On September 22, 2011, the Company issued 1,372,119 shares of common stock for $100,000 ($0.07/share).

On November 9, 2011, the Company issued 1,314,406 shares of common stock for $100,000 ($0.08/share).

On December 16, 2011, the Company issued 1,543,210 shares of common stock for $100,000 ($0.06/share).

On January 20, 2012, the Company issued 1,562,500 shares of common stock for $100,000 ($0.06/share).

On April 19, 2012, the Company issued 2,403,846 shares of common stock for $100,000 ($0.06/share).

On May 19, 2012, the Company issued 1,923,077 shares of common stock for $100,000 ($0.05/share).

On June 29, 2012, the Company issued 2,155,172 shares of common stock for $100,000 ($0.04/share).

On December 21, 2012, the Company issued 1,004,832 shares of common stock for $25,000 ($0.02/share).

On February 19, 2013, the Company issued 961,538 shares of common stock for $50,000 ($0.05/share).

On March 4, 2013, the Company issued 945,537 shares of common stock for $50,000 ($0.05/share).

On April 1, 2013, the Company issued 822,368 shares of common stock for $50,000 ($0.06/share).

On April 15, 2013, the Company issued 884,434 shares of common stock for $75,000 ($0.08/share).

During the six months ended June 30, 2013, the Company had to issue an additional 845,800 make-up shares related to a transaction entered into during the year ended December 31, 2012.

(B) Common Stock Issued for Intellectual Property

On April 26, 2006, the Company issued 332,292,000 shares of common stock to its founder having a fair value of $180 ($0.000001/share) in exchange for intellectual property.  The fair value of the patent was determined based upon the historical cost of the intellectual property contributed by the founder.

(C) Common Stock Issued for Services

On May 8, 2006, the Company entered into a license agreement for research and development. Pursuant to the terms of the agreement, the Company issued 17,500,000 shares of common stock upon execution of the agreement. The Company also received a five-year call option from the license holder to repurchase 7,000,000 common shares at an exercise price of $150,000 or $.02 per share. The option gives the Company the right, but not the obligation to repurchase the shares of common stock.  The call option expires May 4, 2011. As of June 30, 2011 the value of the stock was $.07 per share.  The Company does not have the obligation to repurchase the shares.

On July 1, 2006 the Company entered into a five year consulting agreement for research and development. Pursuant to the terms of the agreement, the Company paid 700,000 shares of common stock upon execution.  These shares had a fair value of $5,600 ($0.01/share) based upon the recent cash offering price.  Additionally, 2,000,000 shares of common stock were issued on May 18, 2007 with a fair value of $16,000 ($0.01/share).   As of December 31, 2008, the Company issued 600,000 shares of common stock for consulting services rendered with a fair value of $6,000 ($0.01/share).  On January 15, 2008 the Company authorized the issuance of 400,000 shares of common stock for consulting services rendered with a fair value of $4,000 ($0.01/share).

On July 1, 2009, the issuance of 280,000 shares was approved by the board of directors as repayment for services previously provided to the Company by a consultant having a fair value of $14,000 ($0.05/share) in accordance with a consulting agreement (See Note 9(C)).

On July 1, 2009, the issuance of 482,825 shares was approved by the board of directors as partial payment for services previously provided to the Company by a consultant in accordance with a consulting agreement.  The total amount of issuable shares for the consultant is 1,122,311 shares, which includes 400,000 issuable shares previously approved by the board of directors and 239,486 shares were approved to be issued on November 19, 2009 for a fair value of $18,000 (See Note 9(C)).

On August 3, 2009, the Company entered into an agreement with a consultant to provide investor relations services.  On October 5, 2009 the Company issued 10,000,000 shares with a fair value of $200,000 ($0.02/share) to a consultant for investor relations to be provided over a term of 180 days.  The Company started receiving services beginning October 5, 2009.  As of March 31, 2010 $200,000 was recorded (See Note 9(D)).

On January 15, 2010 the Company issued 500,000 shares with a fair value of $5,000 ($0.01/share) to a consultant for investor relations to be provided over a term of 12 months once certain conditions are met.  As of March 31, 2010, $5,000 was recognized as deferred compensation (See Note 9).

On May 21, 2010 the Company issued 40,000 shares with a fair value of $400 ($0.01/share) to a consultant for research and development services (See Note 9(C )).

On July 30, 2010 the Company issued 2,400,000 shares with a fair value of $30,000 ($0.0125/share) to a consultant for legal services incurred in behalf of the Company.

On August 26, 2010 the Company issued 280,000 shares with a fair value of $14,000 ($0.05/share) to a consultant for research and development services provided in the past.

On August 26, 2010 the Company issued 985,915 shares with a fair value of $14,000 ($0.0142/share) to a consultant for research and development services provided in the past (See Note 9 (C)).

On August 26, 2010 the Company issued 4,500,000 shares with a fair value of $90,000 ($0.02/share) to a consultant for research and development services (See Note 9 (C)).

On August 26, 2010 the Company issued 10,000,000 shares with a fair value of $200,000 ($0.02/share) to a consultant for research and development services (See Note 9 (C)).

On September 16, 2010, the Company entered into an agreement with a consultant to provide technical support.  On September 16, 2010 the Company issued 100,000 shares, as a sign on bonus, with a fair value of $15,000 ($0.15/share) to the consultant for technical support to be provided over the next 3 years. In addition, the consultant shall receive 30,000 shares for three years commencing on or about September 10 of each of the next three years (See Note 9(C)).

On September 16, 2010, the Company entered into an agreement with a consultant to provide technical support.  On September 16, 2010 the Company issued 100,000 shares, as a sign on bonus, with a fair value of $15,000 ($0.15/share) to the consultant for technical support to be provided over the next 3 years. In addition, the consultant shall receive 30,000 shares for three years commencing on or about September 10 of each of the next three years (See Note 9(C)).

On September 23, 2010 the Company issued 387,500 shares with a fair value of $31,000 ($0.08/share) to a consultant for legal services incurred on behalf of the Company.

On April 1, 2011 the Company issued 1,000,000 shares with a fair value of $70,000 ($0.07/share) to a consultant for research and development services.

On April 18, 2011, the Company issued 1,029,412 shares of stock with a fair value of $70,000 based on the average trading price over a 30 day period for a research and development consulting agreement.

On October 28, 2011, the Company issued 2,200,000 shares of stock with a fair value of $242,000 ($0.11/share) to obtain the use of a license.

On May 24, 2012 the Company issued 3,200,000 shares with a fair value of $192,000 ($0.06/share) to a consultants for research and development services.

On May 24, 2012 the Company issued 300,000 shares with a fair value of $18,000 ($0.06/share) to a consultant for research and development services provided in the past.

On May 24, 2012 the Company issued 3,000,000 shares with a fair value of $300,000 ($0.10/share) to a consultant for research and development services provided in the past.

On December 18, 2012 the Company issued 1,000,000 shares with a fair value of $40,000 ($0.04/share) to a consultant for research and development services provided in the past.

(D) Cancellation and Retirement of Common Stock

On December 29, 2006, the Company’s founder returned 11,666,500 shares of common stock to the Company.  These shares were cancelled and retired.  Accordingly, the net effect on equity is $0.

(E) Common Stock Warrants (Restated)

During 2006, the Company issued 6,000,000 warrants to an officer under his employment agreement.   The Company recognized an expense of $126,435 for the period from inception to December 31, 2006.  The Company recorded the fair value of the warrants  based on the fair value of each warrant grant estimated on the date of grant using the Black-Scholes option pricing model with the following weighted average assumptions used for grants in 2006, dividend yield of zero, expected volatility of 183%; risk-free interest rates of 4.98%, expected life of one year. The warrants vested immediately.   The options expire between 5 and 9 years from the date of issuance and have an exercise price of between $.21 and $.40 per share. During November 2006, the Company and the officer entered into an amendment to the employment agreement whereby all the warrants were retired.

On July 29, 2010, the Company issued a warrant for 20,000,000 common shares in connection to a consulting agreement. The warrant was value at $200,000, the fair value of the services to be provided pursuant to the agreement. The warrant has a term of 2 years.

On October 4, 2010, the Company issued 5,177,801 shares in connection with the cashless exercise of the 6,000,000 warrants.

On May 11, 2011, the Company issued 19,767,985 shares in connection with the cashless exercise of the 20,000,000 warrants.

On November 21, 20112012, the Company issued 10-year warrants for 10,000,000 shares with a consultant, with an exercise price of $0.001 per share. The warrants were granted for services rendered (See Notes 2 and 8(D)). The warrants had a fair value of $400,000, based upon the Black-Scholes option-pricing model. The Company used the following weighted average assumptions:

Expected dividends

0

%

Expected volatility

283.23

%

Expected term

10 years

Risk free interest rate

1.69

%

Expected forfeitures

0

%

Number of Warrants

Weighted Average Exercise Price

Weighted Average Remaining Contractual Life (in Years)

Balance, December 31, 2011

-

$

-

Granted

10,000,000

0.001

Exercised

Cancelled/Forfeited

-

-

Balance, December 31, 2012

10,000,000

0.001

9.9

Granted

-

$

-

Exercised

-

$

-

Cancelled/Forfeited

-

Balance, June 30, 2013

10,000,000

$

0.001

9.4

Intrinsic Value

590,000

For the six months ended June 30, 2013, the following warrants were outstanding:

Exercise

Warrants

Warrants

Remaining

Aggregate

Price

Outstanding

Exercisable

Contractual Life

Intrinsic Value

$

0.001

10,000,000

10,000,000

9.4

$

590,000

For the year ended December 31, 2012, the following warrants were outstanding:

Weighted Average

Exercise

Warrants

Warrants

Remaining

Aggregate

Price

Outstanding

Exercisable

Contractual Life

Intrinsic Value

$

0.001

10,000,000

10,000,000

9.895890411

$

365,000

(F)  Amendment to Articles of Incorporation

On February 16, 2009, the Company amended its articles of incorporation to amend the number and class of shares the Company is authorized to issue as follows:

●

Common stock Class A, unlimited number of shares authorized, no par value

●

Common stock Class B, unlimited number of shares authorized, no par value

●

Preferred stock, unlimited number of shares authorized, no par value

(G) Stock Split Effected in the Form of a Stock Dividend

On March 23, 2009, the Company's Board of Directors declared a nine-for-one stock split to be effected in the form of a dividend.  The stock dividend was distributed to shareholders of record as of April 27, 2009.  A total of 449,773,650 shares of common stock were issued.  All basic and diluted loss per share and average shares outstanding information has been adjusted to reflect the aforementioned stock dividend.

9_COMMITMENTS_AND_CONTINGENCIE

9. COMMITMENTS AND CONTINGENCIES	6 Months Ended
	Jun. 30, 2013
Commitments and Contingencies Disclosure [Abstract]	'
COMMITMENTS AND CONTINGENCIES	'
	On March 18, 2010, the Company entered into an addendum to the employment agreement whereby the Company will reimburse the employee and his family for up to $20,000 of out of pocket medical and dental care costs, including prescription costs or co-pays.
	On September 30, 2010, the Company entered into an addendum to the employment agreement whereby all but $250,000 of unpaid back salary will be forgiven by the principal stockholder.  The addendum also eliminated the various milestone achievement awards from the prior employment agreements.  In addition, the addendum reduced the interest rate to 3% per year.  Further, the conversion rights for unpaid back salary where amended whereby the principal shareholder has the option to convert any accured salary into Class “A” Common stock by dividing the dollar value of the debt to be converted to stock by the closing price of the stock on the date that the conversion notice is received by the Company.  This amemdment effectively eliminated any beneficial conversion features related to accrued salary of September 30, 2010.  In exchange the Company will issue 10,000,000 preferred shares to the principal stockholder no later than September 30, 2011, that date was extended by mutual agreement to December 31, 2012.  The agreement was subsequently extended to October 30, 2013.
	On November 10, 2010, the Company entered into an addendum to the employment agreement, effective January 1, 2011 through the December 31, 2015.  The term of the agreement is a five year period at an annual salary of $210,000.  There is a 6% annual increase.  The employee is also to receive a 20% bonsus based on the annual based salary.  Any stock, stock options bonuses have to be approved by the board of directors (See Note 8).
	(B)License Agreement
	On May 8, 2006, the Company entered into a license agreement.  Pursuant to the terms of the agreement, the Company paid a non-refundable license fee of $10,000. The Company will pay a license maintenance fee of $10,000 on the one year anniversary of this agreement and each year thereafter.  The Company will pay an annual research fee of $13,700 with first payment due January 2007, then on each subsequent anniversary of the effective date commencing May 4, 2007.  Pursuant to the terms of the agreement the Company may be required to pay additional fees aggregating up to a maximum of $10,000 a year for patent maintenance and prosecution relating to the licensed intellectual property.
	On October 28, 2011, the Company entered into a license agreement with the University of Notre Dame. Under the agreement, the Company received exclusive and non-exclusive rights to certain spider silk technologies including commercial rights with the right to sublicense such intellectual property. In consideration of the licenses granted under the agreement, the Company agreed to issue to the University of Notre Dame 2,200,000 shares of its common stock and to pay a royalty of 2% of net sales. In addition, the Company is in negotiations with the University of Notre Dame for a research and development agreement. Upon successfully entering into such an agreement, the Company anticipates it could owe approximately $144,000.
	The license agreement has a term of 20 years which can be extended on an annual basis after that. It can be terminated by the University of Notre Dame if the Company defaults on its obligations under the agreement and fails to cure such default within 90 days of a written notice by the university. The Company can terminate the agreement upon a 90 day written notice subject to payment of a termination fee of $5,000 if the termination takes place within 2 years after its effectiveness, $10,000 if the termination takes place within 4 years after its effectiveness and $20,000 if the Agreement is terminated after 4 years.
	(C)Royalty and Research Agreements
	On September 16, 2010, the Company entered into an agreement with a consultant for research and development.  On September 16, 2010 the Company issued 100,000 shares as a sign on bonus with a fair value of $15,000 ($0.15/share) to the consultant for technical support to be provided over the next 3 years. In addition, the consultant shall receive 30,000 shares for three years commencing on or about September 10 of each of the next three years (See Note 8(C)).
	On September 16, 2010, the Company entered into an agreement with a consultant for research and development.  On September 16, 2010 the Company issued 100,000 shares as a sign on bonus with a fair value of $15,000 ($0.15/share) to the consultant for technical support to be provided over the next 3 years. In addition, the consultant shall receive 30,000 shares for three years commencing on or about September 10 of each of the next three years (See Note 8(C)).
	On May 21, 2010 the Company entered into a three year consulting agreement for research and development.   Pursuant to the terms of the agreement, the Company is required to issue 40,000 shares upon the execution of the agreement and subsequently 10,000 shares per year during the three year term of the agreement.  The annual payment of 10,000 shares for the three years begins on Janaury15 of each of the next three years following the execution of this agreement.
	On May 1, 2008 the Company entered into a five year consulting agreement for research and development. Pursuant to the terms of the agreement, the Company will be required to pay $1,000 per month, or at the Company’s option, the consulting fee may be paid in the form of Company common stock based upon the greater of $0.05 per share or the average of the closing price of the Company’s shares over the five days preceding such stock issuance.  As of June 30, 2011 the Company had accrued $17,000 of accounts payable for the services provided of which was paid in common stock on July 1, 2009 (See Note 7(C)).  As of June 30, 2011 the Company issued 280,000 shares of common stock in exchange for $14,000 of accounts payable for the services performed.  As of December 31, 2011, $12,000 was accrued for unpaid services provided during the year.
	On December 26, 2006, the Company entered into an addendum to the intellectual property transfer agreement with an officer.  In consideration of the Company issuing either 200,000 preferred shares with the following preferences; no dividends and voting rights equal to 100 common shares per share of preferred stock or the payment of $120,000, the officer agreed to terminate the royalty payments due under the agreement and give title to the exclusive license for the non protective apparel use of the intellectual property to the Company.  On the date of the agreement, the Company did not have any preferred stock authorized with the required preferences.  In accordance with FASB Accounting Standards Codification No 480, Distinguishing Liabilities from Equity, the Company determined that the present value of the payment of $120,000 that was due on December 26, 2007, the one year anniversary of the addendum, should be recorded as an accrued expense until such time as the Company has the ability to assert that it has preferred shares authorized.  As of March 31, 2010, the Company has recorded $120,000 in accrued expenses- related party.  On December 21, 2007 the officer extended the due date to July 30, 2008.  On May 30, 2008 the officer extended the due date to December 31, 2008.  On October 10, 2008, the officer extended the due date to the earlier of (a) March 30, 2010 or (b) upon demand by the officer.  The due date was extended to March 31, 2011.  On September 8, 2009, a payment of $15,000 was paid to the officer. An additional payment of $10,000 was made on October 19, 2009 and December 1, 2009, respectfully.  Additionally, the accrued expenses are accruing 7% interest per year. On January 15, 2010 an additional payment of $10,000 was made.  During the quarter ending September 30, 2010 an additional payment of $8,000 was made. During the quarter ending September 30,2012 an additional payment of $1,000 was made.  As of June 30, 2013 the outstanding balance is $66,000. As of June 30, 2013, the Company recorded interest expense and related accrued interest payable of $1,005 (See Note 10).
	On February 1, 2007 the Company entered into a consulting agreement for research and development for period of one year at a cost of $150,000.  In April 2008, this agreement was extended through March 31, 2009 on a cost reimbursement basis.  Reimbursements are to be made quarterly and are not to exceed $35,000.  On March 1, 2010 the Company entered into a one year consulting agreement for research and development. Pursuant to the terms of the agreement, the Company was  required to pay up to $150,000 in research and development fees on a cost reimbursement basis.   The agreement expired on February 28, 2011 (See Note 10).
	On June 6, 2012 the Company entered into a consulting agreement for intellectual property and collaborative research and development with an American university.  The agreement covers ongoing research and development work performed by the university at the Company’s behest and with the Company’s assistance from May 1, 2011 and extending through April 30, 2013.  Pursuant to the terms of the agreement the Company will be required to pay approximately $637,984 for research and development over the two year period. For the year ended December 31, 2012 the Company paid $465,293 in research and development fees.  For the six months ended June 30, 2013 the Company paid $210,000 in research and development fees.
	On July 1, 2006 the Company entered into a five year consulting agreement for research and development. Pursuant to the terms of the agreement, the Company paid 700,000 shares of common stock upon execution.  These shares had a fair value of $5,600 ($0.01/share) based upon the recent cash offering price.  Additionally, 2,000,000 shares of common stock were issued on May 18, 2007 with a fair value of $16,000 ($0.01/share).   As of December 31, 2008, the Company issued 600,000 shares of common stock for consulting services rendered with a fair value of $6,000 ($0.01/share).  On January 15, 2008 the Company authorized the issuance of 400,000 shares of common stock for consulting services rendered with a fair value of $4,000 ($0.01/share).   On July 1, 2009, the issuance of 482,825 shares was approved by the board of directors as partial payment for services previously provided to the Company by a consultant in accordance with a consulting agreement.  The total amount of issuable shares for the consultant is 1,122,311 shares, which includes 400,000 issuable shares previously approved by the board of directors and 239,486 shares approved to be issued in November 2009. On August 26, 2010, the Company entered into an addendum to the employment agreement where the monthly fee to the consultant was increased to $10,000 per month starting on September 1, 2010.  On August 26, 2010 the Company issued 985,915 shares with a fair value of $14,000 ($0.0142/share) to a consultant for research and development services provided in the past In addition, On August 26, 2010 the Company issued 4,500,000 bonus shares with a fair value of $90,000 ($0.02/share) to a consultant for research and development services and 10,000,000 shares with a fair value of $200,000 ($0.02/share) to a consultant for research and development services (See Note 8(C) ).
	(D)Consulting Agreement
	On August 3, 2009, the Company entered into an agreement with a consultant to provide investor relations services.  On October 5, 2009 the Company issued 10,000,000 shares with a fair value of $200,000 ($0.02/share) to a consultant for investor relations to be provided over a term of 180 days.  The Company started receiving services beginning October 5, 2009.  As of September 30, 2011, $200,000 was recorded as a consulting expense (See Note7(C)).
	On January 15, 2010, the Company entered into an agreement with a consultant to provide investor relations services in exchange for 500,000 shares or $15,000.  On January 15, 2010 the Company issued 500,000 shares with a fair value of $5,000 ($0.01/share) to a consultant for investor relations to be provided over a term of 12 months (See Note 8(C)).
	On July 29, 2010, the Company entered into an agreement with a consultant to provide investor relations services in exchange for a warrant for 20,000,000 common shares. The value of the services was $200,000, which approximated fair value.  The agreement will remain in effect until January 29, 2011(See Note 8(E)).
	On April 8, 2011 the Company entered into a five year consulting agreement for research and development. Pursuant to the terms of the agreement, the Company has to issue within 10 days following the effective date $70,000 worth of stock and pay a license fee of $30,000.  The Company has a five year right to exercise the option for a commercial medical license or the commercial textile license.  The fee for the first license is a $289,000 and shares equivalent in value to $675,000.  The fee for a second commercial license is $75,000 and shares equivalent in value to $175,000.  All payments are non-refundable. On April 18, 2011, the Company issued 1,029,412 shares of stock with a fair value of $70,000 based on the average trading price over a 30 day period.
	On September 30, 2011 the Company entered into an addendum to an agreement with a consultant, superseding previous agreements, to provide research and development for a term of four years. Pursuant to the terms of the agreement, the Company will issue 3,000,000 shares of the Company’s common stock and replaces any stock currently owed to the consultant pursuant to consulting fee provisions of prior agreements.  Additionally the Company will issue one million shares of the Company’s common stock per year as a consulting fee on the annual anniversary of this agreement or at the Company’s option, pay an annual consulting fee of $100,000.  As of September 30, 2011, the fair value of the Company’s shares of common stock was $0.10 per share and the Company owed the consultant $130,000.  Accordingly, the Company has recorded an additional liability to the consultant of $170,000 as of September 30, 2011. For the year ended December 31, 2012 the Company issued 4,000,000 shares with a fair value of $340,000 to a consultant for research and development services provided in the past.
	(E)Operating Lease Agreement
	On April 1, 2012 the Company executed a one-year non-cancelable operating lease for its corporate office space. The lease began on April 1, 2012 and expired on March 31, 2013.   Total base rent due during the term of the lease is $12,000.
	Rent expense for the six months ended June 30, 2013 is 6,640.

10_RELATED_PARTY_TRANSACTIONS

10. RELATED PARTY TRANSACTIONS	6 Months Ended
	Jun. 30, 2013
Related Party Transactions [Abstract]	'
RELATED PARTY TRANSACTIONS	'
	On October 6, 2006 the Company received $10,000 from a principal stockholder.    Pursuant to the terms of the loan, the advance bears interest at 12%, is unsecured and matured on May 1, 2007. At June 30, 2011 the Company recorded interest expense and related accrued interest payable of $776.   As of June 30, 2011, the loan principal was repaid in full.
	On December 26, 2006, the Company entered into an addendum to the intellectual property transfer agreement with an officer.  In consideration of the Company issuing either 200,000 preferred shares with the following preferences; no dividends and voting rights equal to 100 common shares per share of preferred stock or the payment of $120,000, the officer agreed to terminate the royalty payments due under the agreement and give title to the exclusive license for the non protective apparel use of the intellectual property to the Company.  On the date of the agreement, the Company did not have any preferred stock authorized with the required preferences.  In accordance with In accordance with FASB Accounting Standards Codification No. 480, Distinguishing Liabilities from Equity, the Company determined that the present value of the payment of $120,000 that was due on December 26, 2007, the one year anniversary of the addendum, should be recorded as an accrued expense until such time as the Company has the ability to assert that it has preferred shares authorized.  As of March 31, 2010, the Company has recorded $120,000 in royalty agreement payable- related party.  On December 21, 2007 the officer extended the due date to July 30, 2008.  On May 30, 2008 the officer extended the due date to March 31, 2009.  On October 10, 2008, the officer extended the due date to the earlier of (a) March 30, 2010 or (b) upon demand by the officer. On March 30, 2010, the officer extended the due date to the earlier of (a) March 30, 2010 or (b) upon demand by the officer.  On September 8, 2009, a payment of $15,000 was paid to the officer. On October 19, 2009 and December 1, 2009, $10,000 was paid to the officer respectfully.  An additional payment of $10,000 was made on January 15, 2010.  During the quarter ending September 30, 2010 an additional payment of $8,000 was made. During the year ended December 31, 2012 an additional payment of $1,000 was made. As of June 30, 2013, the outstanding balance is $66,000.  Additionally, the accrued expenses are accruing 7% interest per year.  As of June 30, 2013 the Company recorded interest expense and related accrued interest payable of $1,005(See Note 9(C)).
	As of June 30, 2013, the Company owes $634,732 in accrued salary to principal stockholder.    On September, 2010, the Company entered into an addendum to the employment agreement whereby all but $250,000 of unpaid back salary will be forgiven by the principal stockholder.  Also, the interest rate was reduced to 3% per year.  In exchange the Company will issue 10,000,000 preferred shares to the principal stockholder no later than September 30, 2011, that date was extended by mutual agreement to December 31, 2012.  The agreement was subsequently extended to October 31, 2013.  As of June 30, 2011, no accrued salary has been converted to Class “A” Common Stock.  On November 10, 2010, the Company entered into an addendum to the employment agreement, effective January 1, 2011 through the December 31, 2015.    The term of the agreement is a five year period at an annual salary of $210,000.  There is a 6% annual increase.  The employee is also to receive a 20% bonsus based on the annual based salary.  Any stock, stock options bonuses have to be approved by the board of directors (See Note 8(A)).
	On February 25, 2013 the Company received $150,000 from a principal stockholder.    Pursuant to the terms of the loan, the advance bears interest at 3%, is unsecured and due on demand. At June 30, 2013 the Company recorded interest expense and related accrued interest payable of $1,543.

11_SUBSEQUENT_EVENTS

11. SUBSEQUENT EVENTS	6 Months Ended
	Jun. 30, 2013
Subsequent Events [Abstract]	'
SUBSEQUENT EVENTS	'
	Management has evaluated subsequent events through August 19, 2013, the date on which the financial statements were available to be issued.
	On July 11, 2013 the Company issued 1,760,563 shares of common stock for $100,000 ($0.06/share).
	On July 25, 2013 the Company issued 1,760,563 shares of common stock for $100,000 ($0.06/share).
	On July 18, 2013, the Company issued 9,857,142 shares in connection with the cashless exercise of the 10,000,000 warrants (See Note8(D)).
	On July 22, 2013, the Company entered into an agreement with a consultant to provide investor relations services in exchange for a warrant for 10,000,000 common shares at $.001 with a cashless provision and a five year term. The value of the services was $10,000, which approximated fair value.  The agreement will remain in effect until July 23, 2013.

1_SUMMARY_OF_SIGNIFICANT_ACCOU1

1. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND ORGANIZATION (Policies)	6 Months Ended
	Jun. 30, 2013
Notes to Financial Statements	'
(A) Basis of Presentation	'
		(A)	Basis of Presentation
	The accompanying unaudited condensed financial statements have been prepared in accordance with accounting principles generally accepted in The United States of America and the rules and regulations of the Securities and Exchange Commission for interim financial information.  Accordingly, they do not include all the information necessary for a comprehensive presentation of financial position and results of operations.
	It is management's opinion, however that all material adjustments (consisting of normal recurring adjustments) have been made which are necessary for a fair financial statements presentation.  The results for the interim period are not necessarily indicative of the results to be expected for the year.
	Activities during the development stage include developing the business plan and raising capital.
(B) Use of Estimates	'
	(B) Use of Estimates
	In preparing financial statements in conformity with generally accepted accounting principles, management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and revenues and expenses during the reported period. Actual results could differ from those estimates.
(C) Cash	'
	(C) Cash
	For purposes of the cash flow statements, the Company considers all highly liquid investments with original maturities of three months or less at the time of purchase to be cash equivalents.
(D) Loss Per Share	'
	(D) Loss Per Share
	Basic and diluted net loss per common share is computed based upon the weighted average common shares outstanding as defined by FASB Accounting Standards Codification No. 260, “Earnings per Share.” As of June 30, 2013 and 2012, warrants were not included in the computation of income/ (loss) per share because their inclusion is anti-dilutive.
(E) Research and Development Costs	'
	(E) Research and Development Costs
	The Company expenses all research and development costs as incurred for which there is no alternative future use. These costs also include the expensing of employee compensation and employee stock based compensation.
(F) Income Taxes	'
	(F) Income Taxes
	The Company accounts for income taxes under FASB Codification Topic 740-10-25 (“ASC 740-10-25”).  Under ASC 740-10-25, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases.  Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled.  Under ASC 740-10-25, the effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date.
	Effective January 1, 2009, the Company adopted guidance regarding accounting for uncertainty in income taxes. This guidance clarifies the accounting for income taxes by prescribing the minimum recognition threshold an income tax position is required to meet before being recognized in the financial statements and applies to all federal or state income tax positions. Each income tax position is assessed using a two step process. A determination is first made as to whether it is more likely than not that the income tax position will be sustained, based upon technical merits, upon examination by the taxing authorities. If the income tax position is expected to meet the more likely than not criteria, the benefit recorded in the financial statements equals the largest amount that is greater than 50% likely to be realized upon its ultimate settlement. As of December 31, 2012 and 2011 there were no amounts that had been accrued in respect to uncertain tax positions.
	None of the Company’s federal or state income tax returns is currently under examination by the Internal Revenue Service (“IRS”) or state authorities.  However, fiscal years 2009 and later remain subject to examination by the IRS and respective states.
(G) Derivative Financial Instruments	'
	(G) Derivative Financial Instruments
	Fair value accounting requires bifurcation of embedded derivative instruments such as conversion features in convertible debt or equity instruments, and measurement of their fair value for accounting purposes. In determining the appropriate fair value, the Company uses the Black-Scholes option-pricing model. In assessing the convertible debt instruments, management determines if the convertible debt host instrument is conventional convertible debt and further if there is a beneficial conversion feature requiring measurement. If the instrument is not considered conventional convertible debt, the Company will continue its evaluation process of these instruments as derivative financial instruments.
	Once determined, derivative liabilities are adjusted to reflect fair value at each reporting period end, with any increase or decrease in the fair value being recorded in results of operations as an adjustment to fair value of derivatives. In addition, the fair value of freestanding derivative instruments such as warrants, are also valued using the Black-Scholes option-pricing model.
(H) Stock-Based Compensation	'
	(H) Stock-Based Compensation
	In December 2004, the FASB issued FASB Accounting Standards Codification No. 718, Compensation – Stock Compensation.  Under FASB Accounting Standards Codification No. 718, companies are required to measure the compensation costs of share-based compensation arrangements based on the grant-date fair value and recognize the costs in the financial statements over the period during which employees are required to provide services. Share-based compensation arrangements include stock options, restricted share plans, performance-based awards, share appreciation rights and employee share purchase plans.  As such, compensation cost is measured on the date of grant at their fair value.  Such compensation amounts, if any, are amortized over the respective vesting periods of the option grant.  The Company applies this statement prospectively.
	Equity instruments (“instruments”) issued to other than employees are recorded on the basis of the fair value of the instruments, as required by FASB Accounting Standards Codification No. 718.  FASB Accounting Standards Codification No. 505, Equity Based Payments to Non-Employees defines the measurement date and recognition period for such instruments.  In general, the measurement date is when either a (a) performance commitment, as defined, is reached or (b) the earlier of (i) the non-employee performance is complete or (ii) the instruments are vested. The measured value related to the instruments is recognized over a period based on the facts and circumstances of each particular grant as defined in the FASB Accounting Standards Codification.
(I) Business Segments	'
	(I) Business Segments
	The Company operates in one segment and therefore segment information is not presented.
(J) Recent Accounting Pronouncements	'
	(J) Recent Accounting Pronouncements
	In February 2013, FASB issued Accounting Standards Update 2013-04, Liabilities (Topic 405): Obligations Resulting from Joint and Several Liability Arrangements for Which the Total Amount of the Obligation Is Fixed at the Reporting Date (a consensus of the FASB Emerging Issues Task Force). This guidance requires an entity to measure obligations resulting from joint and several liability arrangements for which the total amount of the obligation within the scope of this guidance is fixed at the reporting date. This stipulates that (1) it will include the amount the entity agreed to pay for the arrangement between them and the other entities that are also obligated to the liability and (2) any additional amount the entity expects to pay on behalf of the other entities. The objective of this update is to provide guidance for the recognition, measurement, and disclosure of obligations resulting from joint and several liability arrangements. The amendments in this update are effective for fiscal periods (and interim reporting periods within those years) beginning after December 15, 2013. This standard is not expected to have a material impact on the Company’s reported results of operations or financial position.
	In February 2013, FASB issued Accounting Standards Update 2013-02, Comprehensive Income (Topic 220): Reporting of Amounts Reclassified out of Accumulated Other Comprehensive Income. This update requires an entity to provide information about the amount reclassified out of accumulated other comprehensive income by component. The entity is also required to disclose significant amounts reclassified out of accumulated other comprehensive income by the respective line items of net income but only if the amount reclassified is required under U.S. GAAP to be reclassified to net income in its entirety in the same reporting periods. For other amounts that are not required under U.S. GAAP to be reclassified in their entirety to net income, an entity is required to cross-reference to other discourses required under U.S. GAAP that provide additional detail about those amounts. The objective in this Update is to improve the reporting of reclassifications out of accumulated other comprehensive income. The amendments in this update should be applied prospectively for reporting periods beginning after December 15, 2013. This standard is not expected to have a material impact on the Company’s reported results of operations or financial position.
(K) Reclassification	'
	(K) Reclassification
	The 2013 financial statements have been reclassified to conform to the 2012 presentation.
(L) Equipment	'
	(L) Equipment
	The Company values property and equipment at cost and depreciates these assets using the straight-line method over their expected useful life. The Company uses a five year life for automobiles.
	In accordance with FASB Accounting Standards Codification No. 360, Property, Plant and Equipment, the Company carries long-lived assets at the lower of the carrying amount or fair value. Impairment is evaluated by estimating future undiscounted cash flows expected to result from the use of the asset and its eventual disposition. If the sum of the expected undiscounted future cash flow is less than the carrying amount of the assets, an impairment loss is recognized. Fair value, for purposes of calculating impairment, is measured based on estimated future cash flows, discounted at a market rate of interest.
	There were no impairment losses recorded during the three and six months ended June 30, 2013 and 2012.

2_RESTATEMENT_OF_FINANCIAL_STA1

2. RESTATEMENT OF FINANCIAL STATEMENTS (Tables)	6 Months Ended
	Jun. 30, 2013
Restatement Of Financial Statements Tables	'
Schedule of restatement of financial statements	'
	The effect of the restatement on our previously issued audited financial statements as of December 31, 2012 is as follows:
		RESTATED BALANCE SHEET									Note
		As Reported			Adjustments			Restated
	Total Assets	$	78,752		$	-		$	78,752
	Total Liabilities	$	1,213,168		$	-		$	1,213,168
	Commitments and Contingencies
	Stockholders' Deficit
	Preferred stock, no par value; unlimited shares authorized,
	none issued  and outstanding		-			-			-
	Common stock Class A,  no par value; unlimited shares authorized,
	603,269,838 and 586,720,411 shares issued and outstanding, respectively		6,360,920			-			6,360,920
	Common stock Class B,  no par value; unlimited shares authorized,
	no shares issued and outstanding		-			-			-
	Common Stock Issuable, 1,122,311 and 1,122,311 shares, respectively		22,000			-			22,000			1
	Additional paid-in capital		920,337			400,000			1,320,337
	Deferred Compensation		-			-			-
	Deficit accumulated during the development stage		(8,437,673	)		(400,000	)		(8,837,673	)		1
			.
	Total Stockholders' Deficit		(1,134,416	)		-			(1,134,416	)
	Total Liabilities and Stockholders' Deficit	$	78,752		$	-		$	78,752
		RESTATED STATEMENT OF OPERATIONS									Note
		For the Year Ended						For the Year Ended
		31-Dec-12						31-Dec-12
		As Reported			Adjustments			Restated
	Revenue	$	-					$	-
									-
	Operating Expenses								-
	General and Administrative		379,326						379,326
	Public Relations		-			400,000			400,000			1
	Amortization of Debt Discount		-						-
	Professional Fees		48,667						48,667
	Officer's Salary		267,120						267,120
	Contract Settlement		-						-
	Research and Development		465,293						465,293
	Total Operating Expenses		1,160,406			400,000			1,560,406
									-
	Loss from Operations		(1,160,406	)		(400,000	)		(1,560,406	)
									-
	Other Income/(Expenses)								-
	Other income		3,000						3,000
	Interest income		192						192
	Change in fair value of embedded derivative liability		-						-
	Change in fair value of embedded derivative liability-related party		-						-
	Interest expense		(45,707	)					(45,707	)
	Other expense		-						-
	Total Other Income/(Expenses)		(42,515	)		-			(42,515	)
									-
	Net (Income) Loss before Provision for Income Taxes		(1,202,921	)		(400,000	)		(1,602,921	)
									-
	Provision for Income  Taxes		-			-			-
									-
	Net Income (Loss)	$	(1,202,921	)	$	(400,000	)	$	(1,602,921	)
									-
	Net Income (Loss) Per Share  - Basic and Diluted	$	(0.00	)				$	(0.00	)
	Weighted average number of shares outstanding
	during the period - Basic and Diluted		596,143,581						596,143,581
		RESTATED STATEMENT OF OPERATIONS									Note
		For the Period from April 25, 2006 (Inception) to December 31, 2012						For the Period from April 25, 2006 (Inception) to December 31, 2012
		As Reported			Adjustments			Restated
	Revenue	$	-					$	-
									-
	Operating Expenses								-
	General and Administrative		1,939,502						1,939,502
Public Relations		219,890			400,000			619,890			1
Amortization of Debt Discount		120,000						120,000
Professional Fees		335,075						335,075
Officer's Salary		1,603,514						1,603,514
Contract Settlement		107,143						107,143
Research and Development		1,302,009						1,302,009
Total Operating Expenses		5,627,133			400,000			6,027,133
								-
Loss from Operations		(5,627,133	)		(400,000	)		(6,027,133	)
								-
Other Income/(Expenses)								-
Other income		7,881						7,881
Interest income		192						192
Change in fair value of embedded derivative liability		(2,790,185	)					(2,790,185	)
Change in fair value of embedded derivative liability-related party		119,485						119,485
Interest expense		(147,913	)					(147,913	)
Total Other Income/(Expenses)		(2,810,540	)		-			(2,810,540	)
								-
Net (Income) Loss before Provision for Income Taxes		(8,437,673	)		(400,000	)		(8,837,673	)
								-
Provision for Income  Taxes		-			-			-
								-
Net Income (Loss)	$	(8,437,673	)	$	(400,000	)	$	(8,837,673	)
								-
	RESTATED STATEMENTS OF CASH FLOWS									Note
	For the Year Ended						For the Year Ended
	31-Dec-12						31-Dec-12
	As Reported			Adjustments			Restated
Cash Flows From Operating Activities:
Net Loss	$	(1,202,921	)	$	(400,000	)	$	(1,602,921	)		1
Adjustments to reconcile net loss to net cash used in operations
Depreciation expense		5,583						5,583
Stock issuable for services		-						-
Change in Fair Value of Derivative Liability		-						-
Stock issued for services		550,000						550,000
Warrants issued to employees		-						-
Warrants issued to consultants		-			400,000			400,000
Deferred compensation realized		-						-
Changes in operating assets and liabilities:								-
(Increase)Decrease in prepaid expenses		(2,270	)					(2,270	)
(Increase)Decrease in other receivables								-
Increase in accrued expenses and other payables - related party		238,977						238,977
Increase in accounts payable		(152,291	)					(152,291	)
Net Cash Used In Operating Activities		(562,922	)		-			(562,922	)
	RESTATED STATEMENTS OF CASH FLOWS									Note
	For the Period from April 25, 2006 (Inception) to December 31,
	2012						For the Period from April 25, 2006 (Inception) to
							December 31,
							2012
	As Reported			Adjustments			Restated
Cash Flows From Operating Activities:
Net Loss	$	(8,437,673	)	$	(400,000	)	$	(8,837,673	)		1
Adjustments to reconcile net loss to net cash used in operations
Depreciation expense		11,406						11,406
Stock issuable for services		22,000						22,000
Change in Fair Value of Derivative Liability		2,790,703						2,790,703
Stock issued for services		1,458,180						1,458,180
Warrants issued to employees		126,435						126,435
Warrants issued to consultants		168,000			400,000			568,000			1
Deferred compensation realized		200,000						200,000
Changes in operating assets and liabilities:								-
(Increase)Decrease in prepaid expenses		(2,270	)					(2,270	)
Increase in accrued expenses and other payables - related party		1,369,600						1,369,600
Increase in accounts payable		329,226						329,226
Net Cash Used In Operating Activities		(1,964,393	)		-			(1,964,393	)
Note:
1.  Adjustment to recongnize 10,000,000 warrants issued to consultant on November 21, 2012, with fair value of $400,000 (See Note 7(E)).
The effect of the restatement on our previously issued unaudited financial statements as of March 31, 2013 and June 30, 2013 is as follows:
	RESTATED STATEMENT OF OPERATIONS									Note
	For the Period from April 25, 2006 (Inception) to						For the Period from April 25, 2006 (Inception) to
	March 31,						March 31,
	2013						2013
	As Reported			Adjustments			Restated
Revenue	$	-					$	-
								-
Operating Expenses								-
General and Administrative		1,967,043						1,967,043
Public Relations		219,890			400,000			619,890			1
Amortization of Debt Discount		120,000						120,000
Professional Fees		351,942						351,942
Officer's Salary		1,662,503						1,662,503
Contract Settlement		107,143						107,143
Research and Development		1,457,292						1,457,292
Total Operating Expenses		5,885,813			400,000			6,285,813
								-
Loss from Operations		(5,885,813	)		(400,000	)		(6,285,813	)
								-
Other Income/(Expenses)								-
Other income		7,881						7,881
Interest income		192						192
Change in fair value of embedded derivative liability		(2,790,185	)					(2,790,185	)
Change in fair value of embedded derivative liability-related party		119,485						119,485
Interest expense		(164,538	)					(164,538	)
Total Other Income/(Expenses)		(2,827,165	)		-			(2,827,165	)
								-
Net (Income) Loss before Provision for Income Taxes		(8,712,978	)		(400,000	)		(9,112,978	)
								-
Provision for Income  Taxes		-			-			-
								-
Net Income (Loss)	$	(8,712,978	)	$	(400,000	)	$	(9,112,978	)
								-
	RESTATED STATEMENT OF OPERATIONS									Note
	For the Period from April 25, 2006 (Inception) to						For the Period from April 25, 2006 (Inception) to
	30-Jun-13						30-Jun-13
	As Reported			Adjustments			Restated
Revenue	$	-					$	-
								-
Operating Expenses								-
General and Administrative		2,000,326						2,000,326
Public Relations		219,890			400,000			619,890			1
Amortization of Debt Discount		120,000						120,000
Professional Fees		380,547						380,547
Officer's Salary		1,721,402						1,721,402
Contract Settlement		107,143						107,143
Research and Development		1,622,059						1,622,059
Total Operating Expenses		6,171,367			400,000			6,571,367
								-
Loss from Operations		(6,171,367	)		(400,000	)		(6,571,367	)
								-
Other Income/(Expenses)								-
Other income		7,881						7,881
Interest income		239						239
Change in fair value of embedded derivative liability		(2,790,185	)					(2,790,185	)
Change in fair value of embedded derivative liability-related party		119,485						119,485
Interest expense		(181,974	)					(181,974	)
Total Other Income/(Expenses)		(2,844,554	)		-			(2,844,554	)
								-
Net (Income) Loss before Provision for Income Taxes		(9,015,921	)		(400,000	)		(9,415,921	)
								-
Provision for Income  Taxes		-			-			-
								-
Net Income (Loss)	$	(9,015,921	)	$	(400,000	)	$	(9,415,921	)

3_EQUIPMENT_Tables

3. EQUIPMENT (Tables)	6 Months Ended
	Jun. 30, 2013
Property, Plant and Equipment [Abstract]	'
Equipment	'
		As of			As of
		June 30,			December 31,
		2013			2012
	Automobile	$	25,828		$	25,828
	Office Equipment		2,086			2,086
	Less Accumulated Depreciation		(14,175	)		(11,406	)
	Total Property and Equipment	$	13,739		$	16,508

8_STOCKHOLDERS_DEFICIT_Tables

8. STOCKHOLDERS DEFICIT (Tables)	6 Months Ended
	Jun. 30, 2013
Stockholders Deficit Tables	'
Schedule of assumptions for warrants	'
	Expected dividends			0	%
	Expected volatility			283.23	%
	Expected term		10 years
	Risk free interest rate			1.69	%
	Expected forfeitures			0	%
Schedule of warrants activity	'
			Number of Warrants				Weighted Average Exercise Price				Weighted Average Remaining Contractual Life (in Years)
	Balance, December 31, 2011			-			$	-
	Granted			10,000,000				0.001
	Exercised
	Cancelled/Forfeited			-				-
	Balance, December 31, 2012			10,000,000				0.001				9.9
	Granted			-			$	-
	Exercised			-			$	-
	Cancelled/Forfeited			-
	Balance, June 30, 2013			10,000,000			$	0.001				9.4
	Intrinsic Value			590,000
Schedule of warrants outstanding	'
	For the six months ended June 30, 2013, the following warrants were outstanding:
	Exercise				Warrants				Warrants				Remaining		Aggregate
	Price				Outstanding				Exercisable				Contractual Life		Intrinsic Value
	$	0.001				10,000,000				10,000,000				9.4	$	590,000
	For the year ended December 31, 2012, the following warrants were outstanding:
													Weighted Average
	Exercise				Warrants				Warrants				Remaining		Aggregate
	Price				Outstanding				Exercisable				Contractual Life		Intrinsic Value
	$	0.001				10,000,000				10,000,000				9.895890411	$	365,000

1_SUMMARY_OF_SIGNIFICANT_ACCOU2

1. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND ORGANIZATION (Details)	6 Months Ended	12 Months Ended
	Jun. 30, 2013	Dec. 31, 2012
Summary Of Significant Accounting Policies And Organization Details	'	'
Stock Warrants (Exercise price - $0.001/share) excluded from earnings because their inclusion would be anti-dilutive	10,000,000	10,000,000

2_RESTATEMENT_OF_FINANCIAL_STA2

2. RESTATEMENT OF FINANCIAL STATEMENTS (Details) (USD $)	Jun. 30, 2013	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2010	Dec. 31, 2009	Dec. 31, 2008	Dec. 31, 2007	Dec. 31, 2006	Apr. 24, 2006
Total Assets	$139,067	$78,752	'	'	'	'	'	'	'
Total Liabilities	1,626,731	1,213,168	'	'	'	'	'	'	'
Commitments and Contingencies	'	'	'	'	'	'	'	'	'
Preferred stock, no par value; unlimited shares authorized, none issued and outstanding	'	'	'	'	'	'	'	'	'
Common stock Class A, no par value; unlimited shares authorized, 603,269,838 and 586,720,411 shares issued and outstanding, respectively	6,585,920	6,360,920	'	'	'	'	'	'	'
Common stock Class B, no par value; unlimited shares authorized, no shares issued and outstanding	'	'	'	'	'	'	'	'	'
Common Stock Issuable, 1,122,311 and 1,122,311 shares, respectively	22,000	22,000	'	'	'	'	'	'	'
Additional paid-in capital	1,320,337	1,320,337	'	'	'	'	'	'	'
Deficit accumulated during the development stage	9,415,921	8,837,673	'	'	'	'	'	'	'
Total Stockholders' Deficit	-1,487,664	-1,134,416	-906,495	-619,185	-3,174,777	-1,899,353	-182,197	-257,706	'
Total Liabilities and Stockholders' Deficit	139,067	78,752	'	'	'	'	'	'	'
As Reported	'	'	'	'	'	'	'	'	'
Total Assets	'	78,752	'	'	'	'	'	'	'
Total Liabilities	'	1,213,168	'	'	'	'	'	'	'
Commitments and Contingencies	'	'	'	'	'	'	'	'	'
Preferred stock, no par value; unlimited shares authorized, none issued and outstanding	'	'	'	'	'	'	'	'	'
Common stock Class A, no par value; unlimited shares authorized, 603,269,838 and 586,720,411 shares issued and outstanding, respectively	'	6,360,920	'	'	'	'	'	'	'
Common stock Class B, no par value; unlimited shares authorized, no shares issued and outstanding	'	'	'	'	'	'	'	'	'
Common Stock Issuable, 1,122,311 and 1,122,311 shares, respectively	'	22,000	'	'	'	'	'	'	'
Additional paid-in capital	'	920,337	'	'	'	'	'	'	'
Deferred Compensation	'	'	'	'	'	'	'	'	'
Deficit accumulated during the development stage	'	-8,437,673	'	'	'	'	'	'	'
Total Stockholders' Deficit	'	-1,134,416	'	'	'	'	'	'	'
Total Liabilities and Stockholders' Deficit	'	78,752	'	'	'	'	'	'	'
Adjustments	'	'	'	'	'	'	'	'	'
Total Assets	'	'	'	'	'	'	'	'	'
Total Liabilities	'	'	'	'	'	'	'	'	'
Common stock Class A, no par value; unlimited shares authorized, 603,269,838 and 586,720,411 shares issued and outstanding, respectively	'	'	'	'	'	'	'	'	'
Common stock Class B, no par value; unlimited shares authorized, no shares issued and outstanding	'	'	'	'	'	'	'	'	'
Common Stock Issuable, 1,122,311 and 1,122,311 shares, respectively	'	'	'	'	'	'	'	'	'
Additional paid-in capital	'	400,000	'	'	'	'	'	'	'
Deferred Compensation	'	'	'	'	'	'	'	'	'
Deficit accumulated during the development stage	'	-400,000	'	'	'	'	'	'	'
Total Stockholders' Deficit	'	'	'	'	'	'	'	'	'
Total Liabilities and Stockholders' Deficit	'	'	'	'	'	'	'	'	'
Restated	'	'	'	'	'	'	'	'	'
Total Assets	'	78,752	'	'	'	'	'	'	'
Total Liabilities	'	1,213,168	'	'	'	'	'	'	'
Common stock Class A, no par value; unlimited shares authorized, 603,269,838 and 586,720,411 shares issued and outstanding, respectively	'	6,360,920	'	'	'	'	'	'	'
Common stock Class B, no par value; unlimited shares authorized, no shares issued and outstanding	'	'	'	'	'	'	'	'	'
Common Stock Issuable, 1,122,311 and 1,122,311 shares, respectively	'	22,000	'	'	'	'	'	'	'
Additional paid-in capital	'	1,320,337	'	'	'	'	'	'	'
Deferred Compensation	'	'	'	'	'	'	'	'	'
Deficit accumulated during the development stage	'	-8,837,673	'	'	'	'	'	'	'
Total Stockholders' Deficit	'	-1,134,416	'	'	'	'	'	'	'
Total Liabilities and Stockholders' Deficit	'	$78,752	'	'	'	'	'	'	'

2_RESTATEMENT_OF_FINANCIAL_STA3

2. RESTATEMENT OF FINANCIAL STATEMENTS (Details 1) (USD $)	3 Months Ended		6 Months Ended		9 Months Ended	12 Months Ended						83 Months Ended	12 Months Ended	80 Months Ended	83 Months Ended	86 Months Ended	12 Months Ended	80 Months Ended	83 Months Ended	86 Months Ended	12 Months Ended	80 Months Ended	83 Months Ended	86 Months Ended
	Jun. 30, 2013	Jun. 30, 2012	Jun. 30, 2013	Jun. 30, 2012	Dec. 31, 2006	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2010	Dec. 31, 2009	Dec. 31, 2008	Dec. 31, 2007	Jun. 30, 2013	Dec. 31, 2012	Dec. 31, 2012	Mar. 31, 2013	Jun. 30, 2013	Dec. 31, 2012	Dec. 31, 2012	Mar. 31, 2013	Jun. 30, 2013	Dec. 31, 2012	Dec. 31, 2012	Mar. 31, 2013	Jun. 30, 2013
													As Reported	As Reported	As Reported	As Reported	Adjustments	Adjustments	Adjustments	Adjustments	Restated	Restated	Restated	Restated
Revenue	'	'	'	'	'	'	'	'	'	'	'	'	$0	$0	$0	$0	'	'	'	'	$0	$0	$0	$0
Operating Expenses	'	'	'	'	'	'	'	'	'	'	'	'	'	'	'	'	'	'	'	'	'	'	'	'
General and Administrative	33,330	230,176	60,827	275,969	'	'	'	'	'	'	'	2,000,326	379,326	1,939,502	1,967,043	2,000,326	'	'	'	'	379,326	1,939,502	1,967,043	2,000,326
Public Relations	'	'	'	'	'	'	'	'	'	'	'	619,890	0	219,890	219,890	219,890	400,000	400,000	400,000	400,000	400,000	619,890	619,890	619,890
Amortization of Debt Discount	'	'	'	'	'	'	'	'	'	'	'	120,000	0	120,000	120,000	120,000	'	'	'	'	0	120,000	120,000	120,000
Professional Fees	28,605	11,651	45,472	33,248	'	'	'	'	'	'	'	380,547	48,667	335,075	351,942	380,547	'	'	'	'	48,667	335,075	351,942	380,547
Officer's Salary	58,899	50,000	117,888	105,650	'	'	'	'	'	'	'	1,721,402	267,120	1,603,514	1,662,503	1,721,402	'	'	'	'	267,120	1,603,514	1,662,503	1,721,402
Contract Settlement	'	'	'	'	'	'	'	'	'	'	'	-107,143	0	107,143	107,143	107,143	'	'	'	'	0	107,143	107,143	107,143
Research and Development	164,765	210,000	320,050	210,000	'	'	'	'	'	'	'	1,622,059	465,293	1,302,009	1,457,292	1,622,059	'	'	'	'	465,293	1,302,009	1,457,292	1,622,059
Total Operating Expenses	285,599	501,827	544,237	624,867	'	'	'	'	'	'	'	6,571,367	1,160,406	5,627,133	5,885,813	6,171,367	400,000	400,000	400,000	400,000	1,560,406	6,027,133	6,285,813	6,571,367
Loss from Operations	-285,599	-501,827	-544,237	-624,867	'	'	'	'	'	'	'	-6,571,367	-1,160,406	-5,627,133	-5,885,813	-6,171,367	-400,000	-400,000	-400,000	-400,000	-1,560,406	-6,027,133	-6,285,813	-6,571,367
Other Income/(Expenses)	'	'	'	'	'	'	'	'	'	'	'	'	'	'	'	'	'	'	'	'	'	'	'	'
Other income	'	3,000	'	3,000	'	'	'	'	'	'	'	7,881	3,000	7,881	7,881	7,881	'	'	'	'	3,000	7,881	7,881	7,881
Interest income	'	55	47	100	'	'	'	'	'	'	'	239	192	192	192	239	'	'	'	'	192	192	192	239
Change in fair value of embedded derivative liability	'	'	'	'	'	'	'	'	'	'	'	-2,790,185	0	-2,790,185	-2,790,185	-2,790,185	'	'	'	'	0	-2,790,185	-2,790,185	-2,790,185
Change in fair value of embedded derivative liability-related party	'	'	'	'	'	'	'	'	'	'	'	'	0	119,485	119,485	119,485	'	'	'	'	0	119,485	119,485	119,485
Interest expense	17,436	15,036	34,061	30,073	'	'	'	'	'	'	'	181,974	-45,707	-147,913	-164,538	-181,974	'	'	'	'	-45,707	-147,913	-164,538	-181,974
Other expense	'	'	'	'	'	'	'	'	'	'	'	'	0	'	'	'	'	'	'	'	0	'	'	'
Total Other Income/(Expenses)	-17,436	-11,981	-34,014	-26,973	'	'	'	'	'	'	'	-2,844,554	-42,515	-2,810,540	-2,827,165	-2,844,554	0	0	0	0	-42,515	-2,810,540	-2,827,165	-2,844,554
Net (Income) Loss before Provision for Income Taxes	-303,035	-513,808	-578,251	-651,840	'	'	'	'	'	'	'	-9,415,921	-1,202,921	-8,437,673	-8,712,978	-9,015,921	-400,000	-400,000	-400,000	-400,000	-1,602,921	-8,837,673	-9,112,978	-9,415,921
Provision for IncomeB B Taxes	'	'	'	'	'	'	'	'	'	'	'	'	0	0	0	0	0	0	0	0	0	0	0	0
Net Income (Loss)	($303,035)	($513,808)	($578,251)	($651,840)	($530,321)	($1,602,921)	($1,295,310)	($1,782,888)	($1,432,091)	($1,721,156)	($472,986)	($9,415,921)	($1,202,921)	($8,437,673)	($8,712,978)	($9,015,921)	($400,000)	($400,000)	($400,000)	($400,000)	($1,602,921)	($8,837,673)	($9,112,978)	($9,415,921)
Net Income (Loss) Per ShareB B - Basic and Diluted	$0	$0	$0	$0	'	'	'	'	'	'	'	'	$0	'	'	'	'	'	'	'	$0	'	'	'
Weighted average number of shares outstanding during the period - Basic and Diluted	607,591,936	591,010,940	606,208,262	590,839,237	'	'	'	'	'	'	'	'	596,143,581	'	'	'	'	'	'	'	596,143,581	'	'	'

2_RESTATEMENT_OF_FINANCIAL_STA4

2. RESTATEMENT OF FINANCIAL STATEMENTS (Details 2) (USD $)

3 Months Ended

6 Months Ended

9 Months Ended

12 Months Ended

83 Months Ended

12 Months Ended

80 Months Ended

83 Months Ended

86 Months Ended

12 Months Ended

80 Months Ended

83 Months Ended

86 Months Ended

12 Months Ended

80 Months Ended

83 Months Ended

86 Months Ended

Jun. 30, 2013

Jun. 30, 2012

Jun. 30, 2013

Jun. 30, 2012

Dec. 31, 2006

Dec. 31, 2012

Dec. 31, 2011

Dec. 31, 2010

Dec. 31, 2009

Dec. 31, 2008

Dec. 31, 2007

Jun. 30, 2013

Dec. 31, 2012

Dec. 31, 2012

Mar. 31, 2013

Jun. 30, 2013

Dec. 31, 2012

Dec. 31, 2012

Mar. 31, 2013

Jun. 30, 2013

Dec. 31, 2012

Dec. 31, 2012

Mar. 31, 2013

Jun. 30, 2013

As Reported

As Reported

As Reported

As Reported

Adjustments

Adjustments

Adjustments

Adjustments

Restated

Restated

Restated

Restated

Cash Flows From Operating Activities:

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Net Loss

($303,035)

($513,808)

($578,251)

($651,840)

($530,321)

($1,602,921)

($1,295,310)

($1,782,888)

($1,432,091)

($1,721,156)

($472,986)

($9,415,921)

($1,202,921)

($8,437,673)

($8,712,978)

($9,015,921)

($400,000)

($400,000)

($400,000)

($400,000)

($1,602,921)

($8,837,673)

($9,112,978)

($9,415,921)

Adjustments to reconcile net loss to net cash used in operations

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Depreciation expense

'

'

2,769

2,776

'

'

'

'

'

'

'

14,175

5,583

11,406

'

'

'

'

'

'

5,583

11,406

'

'

Stock issuable for services

'

'

'

'

'

'

'

'

'

'

'

'

0

22,000

'

'

'

'

'

'

0

22,000

'

'

Change in Fair Value of Derivative Liability

'

'

'

'

'

'

'

'

'

'

'

'

0

2,790,703

'

'

'

'

'

'

0

2,790,703

'

'

Stock issued for services

'

'

'

510,000

'

'

'

'

'

'

'

1,458,180

550,000

1,458,180

'

'

'

'

'

'

550,000

1,458,180

'

'

Warrants issued to employees

'

'

'

'

'

'

'

'

'

'

'

'

0

126,435

'

'

'

'

'

'

0

126,435

'

'

Warrants issued to consultants

'

'

'

'

'

'

'

'

'

'

'

568,000

0

168,000

'

'

400,000

400,000

'

'

400,000

568,000

'

'

Deferred compensation realized

'

'

'

'

'

'

26,000

250,333

'

'

'

200,000

0

200,000

'

'

'

'

'

'

0

200,000

'

'

Changes in operating assets and liabilities:

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

(Increase)Decrease in prepaid expenses

'

'

693

-4,000

'

'

'

'

'

'

'

-1,577

-2,270

-2,270

'

'

'

'

'

'

-2,270

-2,270

'

'

(Increase)Decrease in other receivables

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

Increase in accrued expenses and other payables - related party

'

'

126,287

70,652

'

'

'

'

'

'

'

1,495,838

238,977

1,369,600

'

'

'

'

'

'

238,977

1,369,600

'

'

Increase in accounts payable

'

'

139,026

-266,828

'

'

'

'

'

'

'

468,252

-152,291

329,226

'

'

'

'

'

'

-152,291

329,226

'

'

Net Cash Used In Operating Activities

'

'

($309,476)

($339,240)

'

'

'

'

'

'

'

($2,273,915)

($562,922)

($1,964,393)

'

'

$0

$0

'

'

($562,922)

($1,964,393)

'

'

3_GOING_CONCERN_Details_Narrat

3. GOING CONCERN (Details Narrative) (USD $)	Jun. 30, 2013
Going Concern Details Narrative	'
Working capital deficiency	($1,493,455)

4_EQUIPMENT_Details

4. EQUIPMENT (Details) (USD $)	Jun. 30, 2013	Dec. 31, 2012
Equipment Details	'	'
Automobile	$25,828	$25,828
Office Equipment	2,086	2,086
Less Accumulated Depreciation	-14,175	-11,406
Total Property and Equipment	$13,739	$16,508

4_EQUIPMENT_Details_Narrative

4. EQUIPMENT (Details Narrative) (USD $)	3 Months Ended		6 Months Ended
	Jun. 30, 2013	Jun. 30, 2012	Jun. 30, 2013	Jun. 30, 2012
Equipment Details Narrative	'	'	'	'
Depreciation and amortization expense	$1,392	$1,378	$2,768	$2,766

8_STOCKHOLDERS_DEFICIT_Details

8. STOCKHOLDERS DEFICIT (Details)	6 Months Ended
	Jun. 30, 2013
Stockholders Deficit Details	'
Expected dividends	0.00%
Expected volatility	283.23%
Expected term	'10 years
Risk free interest rate	1.69%
Expected forfeitures	0.00%

8_STOCKHOLDERS_DEFICIT_Details1

8. STOCKHOLDERSb DEFICIT (Details 1) (USD $)	6 Months Ended	12 Months Ended
	Jun. 30, 2013	Dec. 31, 2012
Weighted Average Exercise Price	'	'
Aggregate Intrinsic Value	$590,000	$365,000
Warrants	'	'
Warrants outstanding, beginning	10,000,000	0
Granted	0	10,000,000
Exercised	0	'
Cancelled/Forfeited	0	0
Warrants outstanding, ending	10,000,000	10,000,000
Weighted Average Exercise Price	'	'
Warrants outstanding, beginning	$0.00	'
Granted	'	$0.00
Warrants outstanding, ending	$0.00	$0.00
Weighted Average Remaining Contractual Life (in Years)	'9 years 4 months 24 days	'9 years 10 months 24 days
Aggregate Intrinsic Value	$990,000	'

8_STOCKHOLDERS_DEFICIT_Details2

8. STOCKHOLDERS DEFICIT (Details 2) (USD $)	Jun. 30, 2013	Dec. 31, 2012
Stockholders Deficit Details 2	'	'
Warrants outstanding	10,000,000	10,000,000
Warrants exercisable	10,000,000	10,000,000
Exercise Price	$0.00	$0.00
Weighted Average Contractual Life	'9 years 4 months 24 days	'9 years 10 months 24 days
Aggregate Intrinsic Value	$590,000	$365,000

9_COMMITMENTS_AND_CONTINGENCIE1

9. COMMITMENTS AND CONTINGENCIES (Details Narrative) (USD $)	6 Months Ended
	Jun. 30, 2013
Commitments And Contingencies Details Narrative	'
Rent expense	$6,640

10_RELATED_PARTY_TRANSACTIONS_

10. RELATED PARTY TRANSACTIONS (Details Narrative) (Principal stockholder, USD $)	Jun. 30, 2013
Principal stockholder	'
Accrued salary to principal stockholder	$634,732